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Editorial
Famil y ph ysic ian are primary health prov ider and the fir t po int of
co ntac t for patients navigaling the hea lthcare y tern. A such, family
medi c ine is the gateway to medica l care fo r most pali ents. Thi fi eld
e ncompasses the widest cope of medi cal practi ce of all specialti e . O ur
rati o na le in choos ing family medi c ine a a the me for thi i ue was thu
based o n o ur desire to hi ghli ght the important and unique nature o f thi
med ica l fi e ld .
The broad pectrum of family med icine all owed o ur contributor to choo e
fro m a wide variety o f top ics of interest, still keeping a ll arti c le ex tre mely
relevant to the field of family med ic ine. With a large proporti o n of medical
stude nts choosi ng family med ic ine for the ir career path s, we are excited to
pre e nt a n is ue th at i inte nded to fo ter inte rest, di scu io n, and
aware ne s of thi s fundamental area of medi cine.
We anti cipate that you will enj oy the article we have included, ra ngi ng
fr m in ightful co mmentari e to intere tin g ca e tudi es to up-to-date
g uide lines and rev iews. We trust that the articles will appeal to all reader ,
regardl ess of your specialty intere tor fi e ld o f tudy.
A a lways we are greatly indebted to the man y individual who made thi
is ue possible. In parti cular, we would like to thank our departmenta l
editors and contributors, cover artist , fac ulty advisors, faculty rev iewer ,
th e Department of Fantily Medi c ine at the Univer ity of W e tern Ontario,
CU Adverti sing, th e Hippocrali c Council at the University of We tern
Ontario. Finally, we th ank o ur dedicated readers for supporting thi i ue
and the UWOMJ . W e e ncourage your re po nse , comment , idea and
questi ons regarding thi i ue at uwo mj @med .uwo .ca.
Enj oy the read!
Your editori a l staff.

__41 .~

E tabtished in l 930, the
UWOMJ provides a forum
for origi nal articles based on
re earc h or clini cal medi cine
of topic or hi stori cal interest.
It is a biannual publicati on
with interdi sciplinary
reader hip that includes
tudent , fac ulty member ,
re idents and speciali sts. At
a ny given time during the
academic year. over 40 past
and pre ent current med ical
tudent Senior and Juni or
Departmental Ed itors recruit,
wri te, ubmit and edit
arti cles.
The UWOMJ has over 20
co nfirmed ph y ician facu lty
reviewer for each issue,
often affi li ated with the
Universi ty of Western
Ontario' Schulich School of
Medicine and Denti try, a
well as hospitals in both
London, Ontario and
Wind or. Ontario. Our
Ad vi ory Board in clude
both nati onall y known
academic and community
phy ician .
Plea e vi it us online at:
www.uwomeds.com/uwomj

HV

Melani e Sproule Hall
Editor in Chief

Amb r Menezes
Senior Editor

We ndy Ng
Senior Editor

Tiffany Kwok
Junior Edjtor

- 4-

Th e Uni versity of Western
Ontario Med ical Journal
(UWOMJ ) i Canada's
econd oldest student run
med ical journal

For infonnati on about
writing for the UWOMJ ,
plea, e fo llow the guidelines
outlined on our web site. The
UWOMJ i a faculty reviewed and peer-reviewed
publication. All editori al
matter in the UWOMJ
represents the opinions of
the a uthor and not
nece saril y those of the
editorial staff and adv isory
board . The editorial staff and
advi sory counc il a s ume no
re ponsibility or liabilit y for
damages ari sing from any
error or o mi sion or from
use of any informati on or
ad vice contained in the
VWOMJ .
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Diagnostic Review
Ambulatory Blood Pressure Monitoring: Indications, Usage, and Interpretation
Jaron Chong, Meds 2010
The di agnosis o f hypertension ha traditi onall y been limi ted to offi ce bl ood pre sure
reading . The ad vent of e lectro ni c blood pressure mo nito rs has prov ided additi o na l
in strument to better profil e a pati ent ' blood pressure. Ambul ato ry Bl ood Pre ure
M o nitoring (ABPM ), in vo lvin g a bl ood pre sure mo nitor worn continuo usly by a
pati e nt over a 24 to 48 hour peri od , prov ides the most compre he n ive profi le of a
patie nt ' bl ood pres ure. ABPM is indi cated in indi viduals with suspected White-Coat
Hypertension or Re i tant Hypertensio n and is a potenti a ll y va luabl e di agnosis
modality. It provides hi gh te mpora l reso luti o n with unbi a ed reporting of bl ood pre ure
to the physician. In additi o n, it is better abl e to characte ri ze nocturnal blood pre sure,
o mething not po ibl e with o ffi ce or ho me/self bl ood pre sure record in gs. T he
Canadi an Hyperte nsio n Educati o n Progra m (C HEP) has defin ed AB PM thresho lds of
hyperten ion to be greater than 135/85 mmH g mean awake B P or greater than 130/80
mmHg fo r mean 24hr BP 's. These thresholds are lower th an the traditi onal o ffi ce
thres holds of 140/90 mm.H g. ABPM results ca n be used to reduce unnecessary anti hyperte n ive therapy a we ll as modi fy dose scheduling to cover ' blind spo t ' in bl ood
pressure regul ati o n. It can also provide additi o nal diagnosti c informati o n regarding the
contributing fac tors to a pati e nt 's re i tant hyperte n io n. For the time being, ABPM i
o nl y moderately cost-effecti ve under certain clini cal indi cati ons a nd thu s is unfunded by
OHIP. No netheless, it remains an additi o nal dimensio n to hypertensio n di agnosis that
all healthcare professio nals should be aware of.

This article has been reviewed by Dr. Louise Moist.

Introduction
Hypertensio n, as defin ed by the Ca nadi a n Hypertensio n Educati o n Program (CHEP), i considered as a
sys tolic bl ood pressure (SBP) of 140nunH g or hi gher and a di asto lic bl ood pre sure (DBP) of 90mmHg or hi gher. 1 It
affects 27% of the Canadi a n adult popul ati o n between the ages of 35 and 64 .2 Hyperten io n is the most important
ri sk facto r for troke as well as the leading preceding conditi o n to heart fa ilure. It is al o a noted ri sk fac tor fo r heart
attacks, arteri a l aneurysms, a nd chroni c re nal failure. 3

Blood Pressure Variability
Blood pressure doe express some norma l vari ability with research by Millar-Craig et al. establi hing the
circadian vari ati o n of bl ood-pressure. Blood pressure ordinaril y pea k during mid-morning, is lowest at ni ght, and
4
ri e before awakening. 25-35% of pati e nts do not express a dip in blood pressure at ni ght and are termed ' nondippers'. Pati e nts witho ut thi s dip have been a ociated with increased sympathe tic acti vity during sleep, worse
prognosis, and ele va ted ri sk of end -organ injury such as progressive re nal insuffi ciency. 5· 6

White-Coat Hypertension
A clinical phe no me no n, known a white-coat hypertensio n (W C HT), exists whereby a n individual' s blood
pres ure ri es in respo nse to anx iety brought o n by a visit to a physic ian's offi ce. 7 A conm1o n definiti o n o f W C HT is
a hi g h bl ood pre sure (BP) in a physic ian' offi ce with a norma l BP at rest or while ambul atory. This can e ither be
defin ed in the hort-term as BP just before and during a vi it or in the lo ng-term as the change between a dail y
8 9
average BP versus BP during a visit. ' In additi on, there sho uld be no e nd-organ damage in order fo r W C HT to be
10
.
d
d1agnose .

Conventional and Home/Self Blood Pressure Monitoring
Conventi o nal bl ood pressure mo nitoring mo t c lassicall y takes o n the fo rm of the merc ury or aneroid
11
sphygmo mano me try performed in the phys ician's offi ce. Collecti ve ly termed as office bl ood pres ure (OBP)

UWOMJ 77(1 ) 2008

-5-

va lues o r ca ual bl ood pre ure readings, they prov id e a s nap ho t o f a pati ent ' s bl ood pressure as performed by a
trained pr fe sio na l.
In rece nt years , there ha been move me nt toward ho me bl ood press ure mo nitoring or self-blood pre sure
monito rin g to erve a an adJ. unc t to offi ce bl ood press ure va lues. Fully automated e lectro ni c bl ood pres ure
~
12
h'l
mo nitors are the most co mmonl y marketed fo r the ir ease-of- use and lack of reporting bias from the pati e nt. W I e
effec ti ve in some capac iti es, limitati ons exjst in term of clini ca l va lidati o n of indi vidual devices a well a variabl e
13
.
mea ure ment c hed ules and number of recordi ng performed by l he paue nt.

Ambulatory Blood Pressure Monitoring (A BPM)
Ambul atory Blood Pres ure Monitorin g (ABPM) differs fro m conventi o nal bl ood pre sure mo nitoring in
th at an e lectro ni c bl ood pre ure mo nitoring dev ice i" worn co ntinuou ly by a patie nt with readings take n at regular
interva ls (Figure J ; Figure 2). AB PM ori ginall y came abo ut as a re earch tool with the fir t recorded me nti o n o f
s uch a device in 1 962 . 1 ~ · 15 T he very first stud y tha t e tabli shed the uperi ority of ambula tory bl ood pre sure
16
reading ' wa performed u ing a modified versio n of the 1962 device by Sokolow and colleague in 1966. Since
that time, ABPMs have co me into greater c lini ca l u e and are now spec ifi call y reco mme nded by Canadian and
1 17
Ameri can cardiovascul ar ocieti e under certain indi catio n . •
ABPM dev ice functi o n by e ither direc tly li stenin g to and interpreting Korolkoff sounds u ing a
rni cropho ne , not unlike conve nti ona l bl ood pres ure mo nitoring, or thr ugh the se nsa ti o n of vibratory signals while
the pressure cuff infl ates. Pressure readings are u ua ll y co llected at 15 to 30 minute interval and stored o n a
co mputer chip for later viewing and interpretati on by the physic ian. Thi s provides the cl ini cian with an unbiased a nd
deta il ed rev iew of the pati e nt ' bl ood pre sure , usua ll y over a 24 to 48 ho ur tudy peri od . 1

Interpretation of ABPM Results
The interpretati o n o f re ults fro m ambul ato ry bl ood pre ure measure me nt i
lig htl y differe nt fro m
traditi o nal o ffi ce bl ood pre ure values. According to the 2007 Ca nad ian Hyperte n io n Ed ucation Program (CHEP)
guide line , a di agnosis o f hyperte nsio n can be made fro m ambul atory bl ood pre sure mo nitoring "if the mean awake
SBP [S y toli c Bl ood Pressure] is 135 mm.Hg or hj gher or the DBP [Di asto lic Bl ood Pre ure] i 85 mmH.g DBP or
higher". ' An alternate determjnati on of hyperte n io n can be made if the mean 24 ho ur bl ood pre sure is "130 mm.H g
1
or hi gher or the DBP i 80mm.H g or higher" . (Fi g ure 3) O f note i th at the e threshold are li ghtl y lower than the
co mmon 140/90 mJnJ-I.g traditi o nall y set for offi ce blood pressure . 17' 19 Thi i to be ex pec ted given the repeated
averaged measureme nts and the rrunirru zati o n o f any po te nti al White- oat effect.

Clinical Indications for ABPM
Given the additi o na l costs inc urred in utili zing ABPM , re earchers and clini cian have devised spec ifi c
indi cati n. for its utili zati n. The mo t ofte n c ited indi cati o n i uspic i n of white-coat hypertensio n. Individuals
with a mbi guous hyperte n io n (i.e. nom1otensive ho me bl ood pressure reading and hyperte n ive office bl ood
pressure readings) can also be betler managed with AB PM data . There are e timate that between 20 to 30 percent
of indi viduals fo und to be hyperte nsive in a ph y ic ian 's o ffi ce are normote n ive at o ther time .20 By recogni zing
these indi vidua ls as norm ten ive r pre-hypertensive, a reducti on in a ntihypertensive medi cation side effect and
18 2 1
,
,
excess costs can be reali zed . ·
Another candid ate for AB PM is res ista nt hype rte n ion, whe n bl ood press ure contro l is not achi eved despite
adeq uate and s ustained anti -hyperte nsive therapy . T hi typica ll y pre e nts a e levated offi ce bl ood pressure , no rma l
20
ho me reading. , and a lac k o f appare nt target-o rgan damage. One eti o logy of resi tant hyperte nsio n e pec ia ll y
suited to 24h ambul atory mo nitorin g is slee p apnea . Hyperte nsive epi odes can occur a a re ult o f apneic pell s. On
AB PM , thi wo uld demo nstrate a a lac k of a nocturn al bl ood pr · ure dip, a findin g no t as easil y o btained with
18
offi ce or ho me bl ood pressure mo nitorin g.
Finall y, a clini cal re carch progres e and ABPM usage bee me more commo npla e, we may ee the
general u age f ABPM in a ll hyperte nsive pati e nt . Already, there is sig nifi cant ev ide nce that ABPM readin o-s may
be a be uer predi ctor of end -orga n damage, cardi ovascul ar event , and morta lity than offi ce bl ood pre ure _2"l.. 23 As
noc turn al bl ood pressure at o appear to pl ay a prognostic ro le, ABPM i able to record what conventi o na l o ffi ce
24
bl ood pressure and casua l ho me bl od pre sure rec rding do not. In additi o n, the 24 h coverage of ABPM ca n
notify a ph ysician of ' blind spots' in hypertensive coverage, necessitating a change in anti -hyperte nsive medi cati o n
25
or do. e . cheduling.

-6-

UWOMJ 77(1 ) 2008

Costs & Availability of ABPM
Fo r a n typical ph ysician' s office, purc hasing a mo nito r a nd assoc iated software ca n range o n average from
18
$4,500 to $5 ,500 USD. ABPM is no t c urrentl y fund ed by OHIP and as s uch there i a no min a l cost as oc iated with
26
its c linica l u age . Ca nadi a n clini cs and ho pita ls typi cal charge a user fee of $50 to $75 C DN per ABPM study . In
co mpari o n, M edicare a nd M edi caid in the United Sta te has reimbursed the co t o f ABPM for pati e nts wi th a
us pec ted diag nos i of White-Coat Hypertensio n. 10
The re have bee n mi xed result regarding the cost-effec ti venes of AB PM . The ori ginal tud y
reconunending M edi care and M edi caid uppo rt o f ABPM fo r suspected White-Coat Hyperten io n pati e nts wa
ba ed on the avoidance o f a nti -hyperten ive drug adverse e ffect as we ll as the be tte r as ess me nt o f cardi ova c ul ar
ri k that ABPM would offer fo r the phys ic ia n. 10 In s upport of the cos t-effecti veness of ABPM is a stud y by K.rako ff
that proj ec t avi ng fo r the usage of AB PM where a nnua l treatme nt costs total a minimum o f $300. Thi co nc lusio n
operates o n the assumpti on that a fracti o n of pati e nts diag nosed with White-Coat Hyperte nsio n wo uld di sco ntinue
27
treatme nt. In another study by Rodri guez- Roca et al. , ABPM wa fo und to be o nl y mo re cost-effecti ve tha n
co nventi o na l bl ood press ure mo nitorin g when the new treatme nt co t of poorl y monitored pati ents was no t
28
inc luded .

Conclusion
Hypertensio n represent a sig nifi cant is ue in modern healthcare with an agin g popul ati o n and ambul ato ry
bl ood pres ure mo nitoring re mains the most acc urate di agnosti c modality avail abl e. Whil e ideal to use in a ll patie nt
with uspec ted hypertensio n, co t-effecti venes guidelines o nl y seem to upport it u e in narrow indi cati ons. In thi
regard , Canada is sli ghtly behind the United States in terms o f publi c fundin g. However, in compa ri so n with ma ny
o ther di agnosti c techno log ies, a ingle ambul atory bl ood pressure tudy is not nearly as pro hibiti ve in co t. For the
time be ing, awarene s of this techn o logy and its appro pri ate indicati o n for use by all healthcare profe io nals i
advi ed with ambul atory bl ood pressures adding another va luab le dimensio n to the mo nitoring of hyperte nsive
patients.
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Figures
FIGURE 1: Ambulatory blood pressure monitor and cuff
18
(Model 90207, SpaceLab Medi ca l, Inc., Issaquah , Wash.)

FIGURE 2: Indi vidual wearing an ambulatory
.
29
bl ood pressure momtor.

FIGURE 3: Thre hold guideline for Ambu latory Blood Pre ure Monitoring (ABPM) uti lizing averaged blood
press ure measurements over the durati on of a stud y; SBP Systolic BP; DBP Diastolic BP. Adapted from the
1
Canadian Hyperte nsion Educa tion Program.
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Profiles
Perspectives from a Community Family Physician: Past, Present and Future
Alysia W. Zhou, Meds 2010
Rural Di covery Week at the University of Western O ntari o (UWO) is a week of
c lini cal expos ure th at provides students wi th their first in ight into co mmunity
medicine, includin g family medicine (FM ). Dr. Joseph Mai i a famil y phy ician in St.
T homa who parti cipated in the 2007 Di scovery Week. He graduated with hi MD and
CCFP at the UWO and is curre ntl y a partner at a large fa mil y med icine clini c in St.
Thomas. Dr. Mai's interest in FM was not ev ide nt until the 4th year of hi s medi cal
tudi es, a fter whi ch hi reside ncy ex perie nce furth er reinforced hi s e nj oyme nt of FM .
Setting up hi practi ce in an under erv iced area all owed him to take adva ntage of
various governme nt ince nti ves , as we ll as the new fundin g for mul as for pri vate
practices that have increased the re munerati on of family doctor to eq ual that of
pecialists in some cases. Additi onall y, there are many opportuniti es to individuali ze
one's FM prac tice to incorporate more speciali zed ta k , whi ch is a great attracti on of
the fi eld for Dr. M ai.

This article has been reviewed by Dr. Joseph Mai.
A group of six stude nts were three days into the University of Western Ontario 's Rural Discovery Week
Program in the mid-sized town of St. Thomas, just south of London . This was to be the ftrst taste of community
medicine that our clas wou ld experience at the e nd of our fi rst year medical c urri c ulum , a nd by far the most
exciting compone nt of the schoo l year.
I was sitting in the waiting room of a large family med icine clinic that included ix fa mil y phy ician , a
busines office, and fi ve nurses. The clinic was cia ified as a Family Health Group, one of several clini c structures
created by the government to give fa mil y doctors greater fl exibility in deciding their clinic a nd payment tructure .
Dr. Joseph Mai is one of the family doctors at thi s clini c. He j oined the tea m shortl y after compl eting hi s
Fami ly Medicine (FM) reside ncy at the UWO in 2003. Pri or to th at, he completed hi s unde rgrad uate training at the
Uni vers ity of Calgary, and subsequentl y pursued hi s Doctor of Medici ne (MD) degree at the UWO. It was during
hi s high school years, however, that Dr. Mai' s aptitude in the sc iences, combined with hi s admirati on for hi s own
fami ly physician, helped him decide to pur ue a career in medi cine. Furthermore, Dr. Mai' undergrad uate research
in physiology a nd in onco logy, which were further e nriched by hi s interacti ons with clinician-scie ntists, helped to
ex pand hi interest in medicine.
Hi s pur uit of medi cine brought him to Ontario and spec ifica ll y the UWO and the Lond on area, where he
co ntinues to practice. With the current governme nt incenti ves for fami ly doctors, I wanted to see why stude nts may
or may not be fl ocki ng to FM a a career, and Dr. Mai' experie nces in the MD program can provide insights fo r
c urrent students. Dr. Mai did not co nsider FM until muc h late r in his medical educati on, which is not surpri sing as it
can be di ffic ult for stude nts to e nvi ion what FM e ncompasses. For in lance, it is ofte n easier to imagi ne the role of
a head and neck surgeon (the na me certainl y provides a clue), a cardi ologist, or a neurosurgeon. So why did Dr. M ai
deci de on FM ? I beli eve hi s reply below illustrates the importa nce of keeping an ope n mind to the various medical
specialti es:
In my 2"d year of medicine, I became interested in otolaryngo logy because I thought I
wanted to be a surgeon and otolary ngo logy had a good clinical compone nt that I wa
interested in. It wo uld have allowed me to work with kids a well a adult and I th ought it
was di versifi ed e nough to keep my interest. In my 3'd year of c lerk hip, after completi ng
the surgery rotation , I didn ' t find it as thrilling as I thought I would , so I started looki ng at
other opti on . I still wanted to be a peciali t at the time becau e there was a sense in
medical schools that fami ly medicine was a default opti on that wa take n if one couldn ' t
get into a specialty.
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I became interested in anesthes ia by the e nd of 3'd year because I liked the lifestyle and
was aware of the pe nding sho rtage o f anestheti ts, which would produce great
opportuniti es in the future. After doing e lectives in anesthesia in 4th year, I found that
ane thesia wa n ' t what I was interested in because it wa fairl y narrow in it scope. I a lso
did an electi ve in fa mily medi cine with a great doc tor in Calgary in 4th year. Thi s helped
me to rea li ze th at the interac ti ons that I wanted in medi cine were those I would ha ve in
famil y medicine.
O n re fl ecting, the part I enj oyed most in ENT wa the c lini cs that I parti cipated in. I didn ' t
li ke the limited pati ent contact in ane the ia and I didn ' t like the lifestyle of surgery. I
fo und that famil y medi cine had the fl exi bility to all o w me to tail o r my medical practice the
way l wanted .
True to hi s fee lings th at FM would combine the e nj oyment of pati ent interacti o n with the medical
compone nt o f treatin g di ease, Dr. Mai's FM reside ncy ex peri e nce further reinforced hi s interest. He tra ined under
Dr. Larry Sc hmidt at St. Joseph ' Famil y Medi ca l Centre in Lo nd o n. where he gained an even greater appreciati on
fo r th e opportuniti es ava il ab le to fami ly ph ysician . Additio nall y, Dr. Schmidt, who had a pri vate prac ti ce for many
years before entering acade mi c medi c ine, wa abl e to hare insig ht into the bu ine s ide of FM with Dr. M ai.
Fo ll owing re ide ncy, Dr. Mai worked in various loc um , inc ludin g the clinic in St. Th o mas where he was
qui ckJ y recruited a a partner. Hi s deci ion to stay in an underserviced area like St. Thomas was upported by the
governme nt at both the prov incial and munic ipa l level :
The government initi ati ve. to he lp attract more phy icians into famil y practice have been
very generou . The remunerati o n has increa ed ub tanti all y and i equi valent to ome
pecia lti es. The initi atives also give ph ys ic ia n help to run the ir practi ce more e ffi c ientl y.
For instance, the governme nt is pay ing the sa lari es for a lli ed health pro fe io na l uch as
nur es and ph y io therapi t to wo rk directl y for us.
I wa abl e to take ad va ntage of the tuiti o n reimbursement a we ll a the underserviced area
grant , whi ch helped me to tart my o wn practice ri g ht away with minimal financial
in vestment of my own.
Indeed , there are now huge incenti ve for graduating medical tude nt a nd tho e completing FM
reside nc ies to practice in under erviced area throug ho ut Ontari o
(www. hea lth .gov.o n. ca/engli sh/prov iders/program/uap/uap_ mn .html ). Neverthe le . prac ti c ing FM in a mall or
mid-s ized community ca n, in so me instance , present it o wn cha ll enge a nd diffi culti es regarding call schedules
and acces to re o urce and to spec iali sts:
Depending o n the community th at you wo rk in , you will have different levels of pecia lty
support. I am fortun ate in St. Th o ma that I have a good core of peciali st that I can
qui ckl y re fer t . A nything mo re spec ia li zed than th at ca n be re ferred to L ndo n, whi ch i
o nl y a hort di lance away. 1 a ls ta ke care f my own pati e nt in the ho pita! and find that
hav ing ho pi ta! pri vil ege i very use ful whe n a very ill pati e nt require mo re
co mprehe nsive care. Thi s is be tter for the pati ent a we ll as giving me the option to treat
ca. e th at cann ot be treated within my c lini c alone. B e ing part o f the ho pita! d oes require
me to be o n ca ll but I haven' t fo und it to be very onero us.
From Dr. M ai ' experi ence, it appear that the government ha fin a lly started li tening to and addres ing
the needs of famil y ph ys icians by all owing greater fl ex ibility with re pect to the type of practi ce, the amo unt of
prac ti ce time, the locati on of practi ce and with who m one dec ides to prac ti ce with. Fo r Dr. Mai , FM pro vides him
with a wide vari ety o f patie nt to make hi s practi ce interesting. Equally impo rtant is that FM allows him to be hi s
own boss; no dealing and hagg lin g with hospita l admini strati on ince knowing all the peciali ts working at the loca l
hospita l all ows him to directl y co ntact them whe n nece ary.
" With the new fundin g model , the re mune ration i also very good ." Dr. M ai pr jects that with the
initiatives c urre ntly underway, FM will become very attractive and will ex peri e nce an increa e in interest and in
recruitme nt. FM all ows one the fl ex ibility to practi ce medi c ine in his or her o wn tyle and give the individual
- I0 -
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freedom to c hange hi s or her inte rest to incorporate more speciali zed ro le and tasks. Finally. it all ows one to have
a life out ide of medicine whil e also being we ll-rem unerated .
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Clinical Procedures
Botulinum toxin injections for cerebral palsy and post-stroke spasticity: an overview
Brent Mallon. Meds 2010
This article has been reviewed by D r. Kellie Leitch.

Introduction
Botulinum Toxi n Type-A (BTX-A) has received much atte nti o n by both medi cal and no n-medi cal
ind ivid uals. C lini ca l prepara ti ons of BTX-A suc h as Botox® (AIIergan Inc, Irvine, C A) are avail abl e fo r cosme tic
use by famil y phys ic ia ns prov iding additi onal educati o n is obtained . Whe n inj ec ted intramusc ul arly, thi s tox.in
prevents the re lease of acetylcholine fro m presy napti c vesicles in the neuro muscular j uncti on, thus temporaril y and
reversibly blockin g musc le fibres. ' Thi ultimate ly leads to weake ned muscul ar contracti o ns.2 A ltho ugh corruno nl y
associated with cos meti cs, BTX-A is becomin g an accepted pharmacologic treatment fo r other conditi o ns, as
injections fo r focal pastic ity econd ary to upper moto r neuro n di sorders suc h as cerebral palsy or stro ke have been
utilized in medicine fo r some time and have been covered by OHIP since 2003 .3 Nonetheless, the evide nced based
support fo r such treatments does not always ex te nd as fa r as randomi zed co ntroll ed tri als (RCT s). It is the purpose
of thi s article to expl ore the techniques for admini stering BTX-A to treat spa ti c muscul ar conditi ons, specificall y
cerebra l palsy or po t- troke, whil e also ex pl orin g the clinical ev ide nce associated with their use.
Muscular Spasticity
Spasticity, one compo ne nt of the upper mo tor neuro n sy nd rome, ha been prev io usly defin ed by J .W .
Lance 4 as "a motor di sorder characteri zed by a velocity-dependent increase in to ni c tretch refl exes with
exaggerated tendo n jerks res ulting in hyper-excitability of the stretch refl ex".2 Ph ysical trauma to the central
nervous system, stroke, multipl e sc lerosis, cerebral palsy, and hereditary spa tic parapae is are a ll commo n causes of
spasti ci ty. 5 As noted by O ' Brie n, spasticity can be viewed as having either ' negati ve ' or 'positi ve' symptoms.
Negative symptoms, such as loss o f dex terity, decreased coordinati o n, or mu c le fa ti gue and weaknes can be
treated co nservati vely throug h ph ysica l therapy or livin g aid s. 5 O n the o ther hand , positi ve symptoms uch as
hyperacti vity, mu sc le spasm, exaggerated deep te ndo n refl exes and the persiste nce of primiti ve re fl exes need to be
treated with either pharmacotherapy (i.e. oral medi cati on, phenol nerve bl ock, intrathecal or oral bac lofe n) or
surgery (tendon surgery or ne uroecto my). 2 ;5 Thu , it i by addressing the po iti ve ympto ms of spasti c ity that BTXA exerts its effect , aimi ng to reduce exaggerated or spastic mu c le ac ti vity to help all ow for stre tching and
antagoni ti c musc le acti vity. 6 Ph y ica ll y, the a im o f the e injecti o n is to re tore bala nce to affected j oints, whil e
2
preventing co ntr~ tures and bo ny deformiti es fro m forming. However, physicians should gauge c lini cal be ne fit by
evaluatin g functi onal improveme nt, re li ef o f sy mpto ms (i.e. pain ), decrea ing the burden of care or facilitating o ther
therapi es (i.e. postponin g urgical interventi o n in paedi atri c patie nts until the ske leto n becomes more mature).
Nonetheless, it is importa nt to e mph as ize th at pharmacothe rapy must be combined with phys iotherapy a nd o ther
forms of co nservati ve manageme nt (s uch as orthose or casting) to achieve the bes t improvement o f pati e nt
o utcomes. 2
As noted above , c lini c ian mu t aim to restore fun cti onal de fi c it while mitigating negative side effects suc h
as excess ive mu c le wea kn ess whe n admini stering BTX-A for pasti c ity. Thus, the muscular target of the inj ec ti o n
must be considered , the appropri ate dose o f toxin must be gauged , and accurate inj ecti o n of BTX-A must be
e nsured ? Phys ical exams sho uld revea l the affec ted muscles, and do in g regime ns have been developed to ouide
2
5
toxin use (see O'B ri en for adult dosin g by muscle). For childre n, to ta l dose o f tox.in sho uld be le s than 400 "'u nits
7
or 12 units/kg of body we ight for BOTOX® , altho ugh signifi cant he terogene ity ex ists within the literature
8
regardin g the units/kg/musc le used .
In terms of locali zing the appropri ate muscle for inj ecti on, anatomi c knowledge and palpati o n is an
accepted technique prov idin g the musc le is large and subcutaneous, while the use of electro myographic guida nce or
electri cal stimul ati on i seen as superi or for small er muscles like those in the forearm or hand due to impro ved
9 10
acc uracy over anatomi c kn owledge alo ne. ; Ho wever, the above techniques may require special training and can
be painful to the pati ent, thus they are of limited use in paediatri c po pul ati o ns. 9

- 12-
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BTX- A inj ecti o ns do no t appear to be a ociated with any maj o r side e ffect , with o nl y focal weakness or nausea
being reported mo re o fte n in the BTX-A gro ups when compared to contro l. 11
However, it is known that ome
pati e nts (< 1%) do no t respo nd to BTX-A whil e up to 10% o f patie nt s may lose the ir respo nse to therapy, po te nti a ll y
due to the prod uc tio n of ne utra li zing anti bodi es.);12 T hus, it i · recomme nded th at ph ysicians limi t the do e to no
mo re tha n o nce every 3 mo nths whil e usin g th e lowest effec ti ve dose po sible. In the event a pati e nt develop
re i La nce to therapy, a c lini c ian llli ght co nsider witc hing bo tulinum tox in serotypes (i.e. BTX-A to BTT-B) as they
are anti geni ca ll y di tinc t. 5; 13

Clinical Evidence
In adult popul ati o n. , the maj ority o f re earch has centered aro und post-stroke o r mul tiple scle ro is pati e nts.
In po t tro ke popul ati o ns, it is believed that BTX-A is effecti ve at managi ng muscul ar to ne . 14 It is less c lear if these
15 20
decreases in tone tran late into mea urabl e lini ca l be nefit for the pati e nts. For exa mpl e, o f the ix . co mpl eted
RCTs publi hed i n peer reviewed j o urna ls and li sted in the Stro ke T ri als Regi try (www. trokecenter.org) , all fo ur
15 17 19
tudie ; . that gauge the impact of BTX-A inj ecti o ns on mu c le to ne/spasti city report stati sticall y sig nifica nt
be ne fit in the interventi o n re lati ve to the control group, allho ugh o ne tud y 17 req uired 1500U dose to achi eve
. .fi1ca nce a nd a no tl1er 19 d 1'd not report co nsiste
. nt re uI ts over Lime.
.
0 n Iy three o f· th e fi1ve stu d 1e
' 15' 17 ·. 19·.20
s1gm
15 19
exalllining fun cti o na l improveme nts report signiti ca nt results, of whi ch two ; did not re port consi te nt res ults over
time (i. e . significance no ted at weeks I , 4 a nd 6 but not 8 and 12). T hus, while it appear studi e are abl e to confi rm
the ne uro toxic effect of BTX- A, the functi o nal impac t of thi therapy is still uncertain .
In paedi atric po pul ati ons. BTX-A inj ecti o n fo r spa ti city i primaril y prov ided to pati e nts with pasti c
cerebral palsy, a popul ati o n where BTX-A's e ffects have been used since the earl y 1990s. 2 1 The u e of BTX-A for
lower limb spasticity is generall y accepted in the literature. 9 For exa mpl e, o ne rece nt RCT eva luating
gastroc nellli o us BTX-A inj ec ti ons fo r pa ti city noted a tati sticall y significant decrease in spasti city a t 8 weeks, an
increa e in dorsiflexion range a nd performance goal at 12 weeks, and an max imum voluntar y torque and gros
21
However, despite measurable gai ns in perfo rmance, patie nts and their falllili es were
mo tor fun cti o n at 24 weeks.
no t sig nifi cantl y happier abo ut the ir perfo rmance goals whe n co mpared to the pl acebo group? 1 The impact of BTXA inj ecti on o n upper-limb spasticity is far le s agreed upon, as a recent ystemati c review fo und that there is
insuffi c ient Level I e vidence to support or refute it u e to impact spa ticity/to ne, range of mo ti o n, or short to
medium fun c tional gains. 6 Thu , it appears that the literature ho uld continue to defi ne the be nefits of BT X-A fo r
upper limb spasticity in CP , while a lso seeking to deterllline wh at therapie adjuncti ve to BTX-A inj ecti o ns will
22
be nefi t C P outcome

Impressions
BTX-A as a pharmacotherapy appear capabl e of reducing spasticity in post-stroke a nd cerebra l pal y
pati ents. Thi s therapy inc ludes the all ev iati on of pain ful musc le spasms, alo ng with postponing surgery in pediatric
popul ati o n by preventing prolo nged contrac tures which could deform a j oint over time. Much hete rogene ity exi ts
regarding the muscles se lected for inj ecti ons, the dose of the inj ecti o ns and the means by whi c h muscles are
ide ntifi ed , whi ch re fl ec ts the pati e nt centered approach of thi s therapy. While evidence confmns BTX-A i able to
reduce muscle to ne or spa ti city in these popul ati ons, the overall functi o nal impact fo r the pati ent is still unc lear.
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botulinum tox in A injections. Developmental Medi cin e & Child Neurology 2006 ; 48(6) :533-539.
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Medicine and the Internet
Computer-assisted learning in medical education
Jordan Glicksman. Meds 2010
Samuel Kraus~, Meds 2009
Dr. Kevin Fung , Department of Otolaryngology
Recent ad vances in techn ology have resulted in an ever-expandin g body of med ica l
lite rature. Whjl e thi growth faces physicia ns and med ical trainee with a c halle nge in
keep ing up to date, the techn o logies th at have facilitated the expansion may also
prov ide doctor a nd stude nt with new method of learning. Computer-a i ted learn ing
has the pote nti al to e nhance medi cal teaching.

This article has been reviewed by Dr. Jason Franklin.
Tec hno logy and communi cati ons have facilitated the treme ndous growth of medi cal literature in recent
1
years. Thi has left med ical profess ional with an ever-ex panding library of knowled ge to be famjli ar with . Whil e
the wea lth of new medi cal informati on presents chall e nge for physicians in keeping up with their re pecti ve fi e ld ,
the techn ologies th at have facilitated the recent expansion may also prov ide an improved means for phys icians to
learn . Computer-a sisted learning (CA L) may hold an important place in the future of med ica l educati on in
undergraduate, pos t-graduate and co ntinuing medical training.
In Canada, undergraduate medical educati on (UME) takes the form of three or four year curric ul a. In thi
time, medical stude nts must acquire the knowledge necessary to pursue post-graduate medi ca l training in both
general and peciali zed reside ncy programs. A a res ult, medi ca l students are forced to acquire vast kn owledge in a
short timeframe. Time restri cti ons in medi cal training are not limited to educati on at the undergraduate level; po tgraduate programs face sirrul ar time constraints. Residency training programs range from two years in family
medicine to ix years for cardiac and neuros urgery. At the e nd o f residency, medica l trainee are expected to feel
comfortabl e as physicians, as they move to practi cing medicine independentl y.

The Current Use of CAL in Medical Education
M edical educators already make use of CAL to provide stude nts with increased exposure in their respective
fi elds. For example, the Computer-Assisted Learnjng in Pedi atrics Program (CLIPP) provides med ica l tude nts with
a case based approach to learning in pediatrics? Program like thi s are gaining popularity, as they allow stude nts to
learn at their own pace. This can all ow for stude nts to learn at a time and locati on that is convenie nt for them, as
long as there i a computer available to work at.
In addition to the impleme ntati on o f CAL in UME, there has been a shift toward the u e of CAL for
continuin g medical educati on (CME). By 2003 , the re were over 11 ,000 online CME cour e available. 3 Practi c ing
physici a ns are required to obtain 400 CME credits over 5 year . There are six ca tegori es of learning that can be u ed
to obtain CME credits. Up to 25 % of thi s require me nt may be met through the "Other Learning Activities" category
which includes acti vitie suc h reading impl e learning material s like j ournal article or u ing un accredited online
co urses.3 Additi onally, accredited CAL modules may be used to obtain credit when they meet the requirements of
the "S tructured Learning Projects" category , which has no cap for credit hours.

Advantages of CAL
CAL application are o f parti c ular value for hi ghly visual content, suc h as de monstrati ons of surgical
procedures and techni cal skill . These kill s typi cally require patial and vi sual coordinati on. Whil e print-based
learning material s are mainl y lirruted to text and image based informati on, CAL can additionall y utili ze multimedi a
capabilitie . CAL can be des igned to incorporate not only text images but also video to enhance tude nt learning . 4
Interactive features of CAL, such as quizzes and learning games, can augme nt the learning process by providing
feedback in a manner that makes student feel comfortabl e?·'
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Costs of Implementation
While the conve ni ence of CAL i attractive, as with a ny new technology, co t i often a co ncern .
Ne vertheless, widespread use of CAL modules can be very cost-effective. For exampl e, in 2005 , the average
develo pme nt co ·t per C LIPP case ess ion was approximately $6, and thi s amount will decrease as more student
co ntinue to u e eac h ca e.2 Jn additi o n, repl aceme nt o f teac hing with CAL has the pote nti al to free up the time of
medica l chool lecturer to teach in o ther capaciti e , uch as small gr oup ses ion . Furthermore, CAL ha the
po tenti al to enhance teaching at di stant locati o n uch as satellite campuses, rural setting and in developing nati o ns.

CAL and Other Learning Methods
Adults have bee n hown to learn optimall y whe n the ir learning i self-directed .6 Thi has resulted in a tre nd
away fr o m traditi o nal lec ture and se minar-ba ed teaching and towards the impl ementati on of more self-directed
learning in medica l curri cul a. In se lf-direc ted learning, the learner ide ntifi es the kn owl edge in which they are
de fi cie nt and then allempt to learn based o n the ir indi vidual needs. C omputers may be able to assist in thi s proce s
by prov iding interac ti ve too ls suc h a qui zzes and learnin g games to a id the stude nt in determining what information
to pursue.
C urre ntl y, there i debate as to the e ffec ti vene o f CAL a a teaching modality. The re are everal studie that
have compared the use o f CAL to other methods o f educati o n. M any o f these studi e show that there i no
ignifi ca nt differe nce in kn ow ledge and skill re tenti on between th o e taught did ac ti ca ll y or by e minar whe n
co mpared to those taught by computer teaching module , but there are so me tudi e ugge ling that o ther form of
teachin g (e.g. didacti c lecture) are till s uperi or. 2· 4· 7·9

The Future of CAL
While re earch
till o ngo in g into the e ffecti vene of CAL fo r medi cal educati on, thi ne w learning
modality is a risin g form of medical teac hing. The As ociati o n of American Medi cal Co ll eges (AAMC) ha
established MedEd Portal, a peer-re vie wed co llecti o n of online teaching tool . Thi re o urce co ntain a databa e of
learning re o urce th at inc lude tutorials, virtual pati e nt and ca e-ba ed learning amo ng other medi cal education
reso urces. 10
Not o nl y doe the MedEd Portal pro vide ea y acce s to CAL modules, but it al o pro vides incentive to
academic phys ic ians to create more CAL too l by prov idin g the ir work with recog niti o n a a peer-re vi ewed
publi catio n. Initi ati ve uch as thi s will like ly increa e the produc ti on of CAL modul e .
The use o f computer-ba ed teachin g in medi cine has the po te nti al to change the way medi cine i taught to
both c urre nt and future generati o ns. Be tween the co nve ni e nce afforded by
L , e nhancement o ver c urre nt
learning modaliti e and increased recogniti o n for publi hin g AL module , there appear to be a bright future for
co mputer-ass i ted learning.
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Histor of Medicine
In the beginning there were apothecaries
A hi storical perspective on the emergence of general practice, the emerge nce of fami ly medicine, and the researc h
agenda of family medicine.

Adam Garber, Meds 2010
Ra-;.a Naqvi, Meds 2009
T he emerge nce of genera l practice a an academic discipline can be traced over a lmo t
two centuries. Maj or eve nts inc lude th e establi hment of the Co ll ege of Genera l
Practice, the identificati on of a defined body of knowledge, the estab li shment of criteri a
fo r ce rtifi cati on, and the change of the co ll ege ' s name to the Coll ege of Famil y
Ph y icians. Of particular importance a we ll is the development of re earch network
and methods that amplify on the unique aspec ts of famil y med ici ne.

This article has been reviewed by Dr. Jeffrey Freeman.
The hi tory of family medi cine in North America is a rather new one. Within its hi story there are periods of
parti cular strength followed by peri od fraught with struggle. Despite these natural ebbs and fl ows, farru ly medi cine
ha advanced med ical understanding and practice both in the cience and the art. That i , family medicine ha
ad vanced the medica l understanding of care for the individual while at the arne time contributin g at a scientifi c and
ep idemiologica l leve l to the body o f medi cal literature. This es ay will outline a brief hi story of the development of
general practice and then family medi cine as it emerged from general practi ce. The essay will also addre the
hi tory of the re earch agenda of family practi ce.
The hi story of general practice begins si milarl y in Canada and the United State in the earl y I 9th century as
both countries clo ely followed the Briti h model. There were physicians, surgeons, and apothecarie 1•2• Ph ys ic ians
were trained through university course work or apprenti ceship and were the progenitors of what we now kn ow as
pecialist 1• For the most part, they provided care for the affluent. The surgeon were trained in barber schoo ls and
were not permitted to pre cribe medicati ons. The apothecaries began as shopkeepers that provided med icines.
Interesti ngly, the apothecari es took on the role of conducting initial clinical investi gati on . The Apothecarie Act of
18 15 advanced both the privileges and the responsibilitie of apothecaries. The Act required candid ates to compl ete
a pharmaceutical chemi stry exam and an exam on the theory of the practice of medici ne. A well , candidates were
1
req uired to complete a five year appre nti ce hip • These requirement all owed the apothecaries to produce income
through the prescription of their med ici nes as well as through their medical practice. It i from the e humble
beginnings that the 'general practiti oner' was born . It is also intere ting to note that David Woods, a renowned
medical writer and educator, uggests that the general practiti oner in North America predate the existence of the
general practiti oner in Europe due to the di spersed ettl ements and mobile co lonies which necessitated the ability of
1
one person to perform surgery, practi ce medi cine, and prescribe medi cati on • The general practitioner enj oyed a
number of years of stability despite some public concerns that due to the lack of a more ri gorous applicati on system,
some general practitioners were under-educated.
By the end of the 19th century however, as the specialist movement gained momentum , some doubts ex isted
as to the future of ge neral practice. Even Sir Willi am Osler expressed thi doubt with respect to general practice in
1
an urban setting • The Flexner Report of 1910 furthered the dominati on of speciali st medi cine. The Flexner Report,
entitled 'Medi ca l Education in the United States and Canada' , led to the standardi zati on of the medical curri culum
and created a link between medi cal schools and establi shed uni versities. As a result mo t clinical teaching was now
12
taki ng place in urban teaching hospital ' • Gutierrez and Scheid point out that by 1935 hospitals became the centre
for teaching and technology, speciali zing was valued highly and required a residency peri od, as the practice of
medicine became a profession for the wealthl. The hospitals, now as speciali st centres, left an uncertai n role for the
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ge neral practiti o ners who co ntinued to practi ce within these very centres to a certain ex tent. The obse io n with
scientific and techn olog ical advancement th at re ulted from the World War II placed even more glory on the
. dl ,2
s houlders of pecialists and the number of stude nt e ntering the fi e ld of genera l practice co nseque ntl y dec I me
·
The College of General Practi ce of Canada, founded in 1954, published a bill of ri ghts for gene ral
practitioners 3 . The College was born o ut of a need to both redefin e the role and revita li ze the image of the general
practitioner. Its initi al mi io n was to improve educati onal tandards and opportuniti es, certifi cati o n tandards,
standards of practi ce and to he lp defin e the general practiti oner's ro le in the hospita l and in the office .
Understandably, be fore impl e me ntati o n of any change, the coll ege strugg led with the prec i e definition o f their
ambiti o us objecti ves. Two centra l diffi culli e proved to be interre lated and took more than a decade to reso lve; first,
the ide ntifi catio n of the body of knowledge that is to be ubsumed under the do main of genera l prac tice and , second,
the is ue s urrounding the coll ege's responsibility to certify its members. It wa in 1967 that a docume nt entitled
Graduate Trainin g in Family Practice both spec ifi ed trainin g requireme nts but also outlined the body of knowledge
that co ncerns famil y ph ys ic ians4 . The co mrnillee re po nsibl e for thi document also enli sted support from Canadian
medical schoo l that year. It i noteworth y th at famil y medi c ine re idence programs at both M cMaster University
and the Uni ve rsity of Weste rn Ontario precede thi document by o ne year. It was a lso in 1967 that the co ll ege was
renamed a the Coll ege of Family Phy ic ian 4 , a name which the coll ege pres id ent , lrwin Bean, o pposed but later
acknowledged its necessi ty. Not surprising ly, thi flurry of progress a nd newfound purpose that seemed to be
weaved into the new name of the co llege, corre lated with the incepti on of Canadian medicare in the 1960s.
Concurrentl y, in the United States, the Milli s Report, the Fo lso m Report, and the Willard Re port were
published independe ntl y by the American Med ica l Associati on in respon se to the increa ing publi c di sapproval of
2
th e fragmented delivery o f care, the inacce ibility to service, and the "deper o na li zati on" of care . Thee report
uggested the need for eac h ci ti zen to posses a personal ph ysic ian who i e n iti ve to life context, the impact of
illness and th e importance of therapeuti c opti o n . It is the opini on of some th at family medi ci ne wa a natural
2
reacti o n to the co unterculture o f the 1960s . Stephens argue alo ng the e line when he peak of agraria ni sm,
5
humani m, utopi ani m, consumeri m, and femini sm in relati o n to the birth o f family medici ne in N orth Ameri a .
The di cuss io n surroundin g re earch in family medi cine began o n after the emergence of family
medi c ine a a di c ipline in Ca nada and the United State 6 . As Herbert ex plain , the re earc h agenda of fami ly
medi cine wa ca ll ed into que Li on as early a 1966. The initial idea wa that research in family medic ine would
focu o n di agno tic te ting, interpretati o n of ympto ms, larger epide rni o log ica l tudi e , a well as deve lopment and
behaviour. However, thi no ti o n was ex panded during the 1970 to include ther areas o f tudy uch a health care
ervice , clini ca l trategies, biomedical sc ie nce , and the o ia l c iences6 . The tudy Group o n Famil y Medi cine
Re earch which took pl ace in 1982 articulated the areas of re earch to which family medi c ine could make unique
co ntributi ons and hi ghlighted th e impo rta nce of re earch e lec tive time for stude nts 7 . Perhap o ne of the mo t
important shifts in the research agend a o f fami ly medi c ine invo lved recogniti o n of the importance of eac h
indi vidu al' s soc io-c ultura l and e nviro nme nta l c ntex t in unde r tanding health and behavi or. Thi idea was
hi ghli ghted by Nigel Sto ll in 1987 and by C ulpepper in 199 1 and req uired a shift in research methods to acco unt for
patient contex t in the de li very of med ica l e rvice and the ex peri e nce of illness 6 .
Sin ce the in cepti o n of famil y practi ce, it wa c lear that the family ph ys ician's office po sessed a remarkable
8
amo unt of data re latin g to di sea e proces e. and o utcome . It i thi s sort o f data, Ryan argued , that could he lp
address centra l issues like diabete , back pain , and the commo n co ld and he lp to " bridge the performance gap" and
"answer rea l-world re earc h que ti o n ". While the pote ntial ha always been recogni zed and ll1e parti cular area of
bene fit have lo ng been deba ted a nd re fin ed, it is the " har ves ting" of the data that has pre e nted o ne of the 0o-reatest
ob tac les to researc h in famil y medi c ine. Until the earl y 1980s, research in fami ly medi cine was praeti ce-ba ed and
therefore, depe nding o n the de mographics of th e surro unding community , o nly certain research questions co uld be
adequate ly addressed. Durin g the 1980s, a m ve wa made towards practice netwo rks and in 1995 the Federation of
Practice-Ba ed Research Networks (FBPRN) was born in the United States with the hope o f poo lin o data
8
brainpower, and resource . Since then practi ce-ba ed re earc h ne tworks are succeeding in the production of o und
re ~arc h databa es. ~erh ap s the _most u se~ul aspect of practi ce_- ba~ed research networks i the ir abi lity to trac k many
pall e nt fo r long pen ods whr ch 1 conducrve to th rough longrtudrnal studr es. Indeed research in family practi ce ha
evo lved to inc lude large scale lo ngitudinal studi es conducted through collaborative re earc h network 9_
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From apothecary to ge nera l pracuu o ner to family doctor, the hi sto ry move toward increas ing
o rgani zati o n a nd increasin g academic ambition . De pite the many important definiti o n and redefinition , a nd the
advanceme nts of mi ssion and respon ibility, a similar vein strin g the hi . tory together. That is, each tep in thi
prog re io n, inc luding the researc h e ndeavours, eem to be guided by the de ire to care for the person whil e
cognizant of intri cate oc ial contex ts.

References

8.

Wood . David . Strength in stud y: An inform al hi tory o f th e Coll ege o f Fami ly Ph y i c i a n ~ o f Canada . Toronto: T .H. Best Printing
Co mpany; 1979. Pg 1-7.
G uti errez, ec ilia a nd Sc heid , Peter. The History o f Famil y Medi c ine and It Impact in U Health are Deli very. Ameri can
Assoc iati on o f Family Ph ysicia n Web ite. http ://www .aa fpfoundati on.org/Pre Builtlfoundati on_g uti errezpaper.pdf
Woods. Dav id . Strength in tud y: An informa l hi story o f the College of Fa mil y Ph y icians of Canada . Toronto: T.H . Be t Priming
ompany; 1979. Pg 9-42.
Wood s, David . Strength in stud y: An informal hi story of the College o f Famil y Phys ic ian of Canada. Toronto: T.H . Best Printing
Company; 1979 . Pg 14 1- 172.
tephen . G. Gay le. Famil y Medi c ine as Counterc ulture. Fam Med 1998 ; 30(9):629-636.
Herbert , Carol P. Re earch in family medi c ine and genera l practi ce: Are we there yet? Briti . h J Gen Pract 2002 ; 52 : 443-446.
Parker on, GR , Barr OM , Bas M., et a l. Meetin g the challenges o f re earc h in famil y medi c ine: Report o f the Stud y Group o n Family
Medi c ine Re earc h. J Fam Pract 1982; 14: I05- 11 3.
Ryan. John , G. Practi ce-based research networkin g for grow ing the ev idence to substanti ate primary care medi cin e. Annal Fam Med

9.

2004; 2 (2): 180- 18 1.
Weel C. Weei-Baumgarten E, Mold J. The importan ce of longitudinal studi es in famjl y medi c ine: experi ences o f two practi ce-ba ed

I.

2.

3.
4.

5.
6.
7.

researc h networks. Journal Ameri can Board of Fam Med.

the shore of Ltke Superior, Thunder Bay offrrs rhe pcrfw
babnc~ of a dp1ami• \\'ark environment .1nd a •·ibram communit)' wirh
many ourmnding culrur.J. r.:crc.l:Jonal. ~ni performing am 1·cnucs.
In t3a. under Bar is drs1lP1ard .~sa· (ulrur;;l ( JpiLal of Canada."

Located on

Through the new Jcutc care rcgicmal health sciences centre, the complex
care and rehab1liranon ho$pital and rhe mulmucr of comrr.t:mry based
h~alth and long t'rm care services, -nmndct Bay provides a cornprchcrL>ivc
arr:l}' of hdrh care services tor :'\orthwcsrcm Ontario.· 'he Norrhcm
Onr:tno School of Mdionc. tht 1rst n w 1:1cd scl:ool in CJn~d.1 m 30
}'<'lrS, tna)' oft~r you arademK npponuniries.
We are currently seeking inrercsrcd candidates, who Jrc eligible for
licensing with rhe College of Physicians and Surgeons of Ontario, in
the following area:

• General and Family Praccice
Qualified candidates mar be eligible for various incentive and/ or wirion
reimbursement grants. Plca.sc fN\\'3rd your curriculum ~~tJ<! wirh rhc
specified posi ion of inreresr. in confiden ce rn:
orinc Oda. Fatmly Ph)'SicJJn Rccrutrer
City of'nltlndcr BJ)'

Phone (807) 625-3155 • FJX (807) 62S-3292
'loU Free 1·888·74 1·3216 · c:n,Jil:ncda@:rhundabJ\'..:J
I

UWOMJ 77(1) 2008

- 19-

Health Promotion
Trans Fats : Health Risks and Policy Considerations
Jonathan Klein, Meds 2010
Jennifer Clara Tang, Meds 2009
Publi c attenti o n has recentl y focused o n the use of trans fats in commercial food
preparati o n and efforts to ban them from commercial products. Trans fa ts have bee n
shown to increa e the ri k of coro nary heart di ease more th an any other calorie source,
inc luding othe r types of fa t. Denmark a nd The Netherl ands have alread y impleme nted
substanti al reducti o n in trans fa t content, th o ugh each co untry achieved thi s goal
thro ugh sub tanti all y di ffere nt means. W e review the che mistry and health ri sks of trans
fa ts a nd di c uss pas ibl e policy opti o ns to reduce trans fat consumptio n in North
Ameri ca.

This article has been reviewed by Dr. Chris Grant.

Introduction
M any recent medi a reports have foc used o n efforts to curb the levels of trans fa ts in food . The issue has
become a hot topi c in publi c di scourse with the recent ban on tran fa ts e nac ted by New York City. These reports
often contain littl e sub tanti ve informati o n in struc ting reader abo ut what trans fats are . what ev idence exists that
they pose a health hazard , and what poli c ies have been implemented to atte mpt to curb their u e. In thi s arti cle, we
seek to provide info rmati o n o n these topics and expl ore existing opti o ns fo r North American society when
co nsiderin g the issue of banning trans fats.
Chemistry and Use in Food
"Fats" is a term u ed by chemists to describe a chemi ca l structure in whi ch 3 "fatty acids" (l o ng chain
carbon molec ul es with a -COO at o ne e nd ) are attached to a ha rt c hai n of 3 carbo n ato ms call ed "glycerol" . From
a nutriti onal viewpoint, " fats" are o ften subdi vided into two categori es: aturated and unsaturated . Un saturated fat
are made of fa tty ac id chains whi ch conta in at least one double bo nd , whil e saturated fa ts have none. These fats are
typi call y liquid at roo m te mperature, since naturall y occ urring unsaturated fa ts typi call y have their do uble bo nd in
the c is ori e ntati o n. Thi s des ignati o n indi cates th at the carbo n ato ms o n either e nd of the do ubl e bo nd are o n the arne
side o f the molecul e creatin g a bent structure preve nting the molec ul e fro m packing c lose ly to o ne ano ther and
raising the compo und 's me lting point. T rans fats are un saturated fa t with carbo n-containing gro up orie nted on
oppos ite sides of the do ubl e bo nd (Fig ure 1). Thi confi gurati o n creates a u·aight c ha in o f carbo n ato ms a llo wing
fo r mo lecul es to pack closely together and ca u ing a so lid state at room te mperature.
An un saturated fa t i termed " po lyun aturated" if it co nta in s two or more multip le bo nds in any o ne fatty
ac id ; un saturated fats with o nl y o ne multipl e bo nd are " mo noun saturated ." Polyunsaturated fats are commo nly
kn own simpl y as " unsaturated" fa ts. T ran fat are a lso ca ll ed trans fa tty ac id (T FAs), since the trans-oriented
do ubl e bo nd is located o n the fatty aci d part of the fa t mo lecul e.
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FIGURE 1: A) Di agra m o f a trans fat , tran -9-oc tadecenoic acid . Note th at the carbon containin g group appear on
oppo ite ides of the double bond . B) Diagram of ci -9-oc tadece noic acid, also ca ll ed oleic acid. The carbo n
contairung groups are on the same ide o f the doubl e bond . Thi s is the c i co nfi gurati o n of the fatty ac id shown in
partA. 1
Tran fat are prod uced indu tri all y from the partial hyd roge nati on of vegetab le oi ls using metal ca taly ts,
e limin ating ome of the double bonds. The advantage of thi s proce s, from the food industry's per pec ti vc , i th at
e liminati on of o me double bond ma kes for vegetab le o il th at are more so lid (" preadabl e") rather than liquid , a nd
which take muc h longer to go rancid (ie . to ha ve their doubl e bo nd o!Ud ized durin g torage). Being ab le to pread
one' ' butte r' with a knife i importa nt to many co n umer ; and he lf life i very important in the food indu try.
Unfortunately, re mova l of ome doubl e bond takes one back toward saturated fat with their undesirab le
hea lth con eque nces; and perh aps worse, the ame processe that remove o me doubl e bonds also create some tra ns
double bond in other pl aces in the fats . The e fat are o ften found in pread suc h as margarine, pas try dough a nd
other co mmerciall y prepared foods. TFAs are found naturall y in small a mounts in the meat of animal whi ch c hew
2
their c ud , such a cattl e and sheep, but they onl y acco unt for aro und 0 .5% of total e ne rgy intake from these meats ' .

Evidence Linking Trans Fats to Heart Disease
Fat are an essenti al part o f a balanced di e t. Canada 's Food Guide recorru11e nds between 30 and 45 mL of
fats per day, tho ugh it tresses that the e hould co me from (po ly)un aturated fats, whil e limiting saturated and tran
4
fat inta ke . tudie have de monstrated th at eating mo tl y polyunsaturated fat and limiting consumpti on o f saturated
a nd trans fat prov ides significant protec ti on against heart di sea e 5 .
Hi gh die tary con umpti on o f tran fat has been linked to increa ed ri k o f myocardi al infarcti on and othe r
coro nary events. Using data on over 85 ,000 fe male nurses from the Nurses Health Stud y, Will ett e t al demon trated
that the re lati ve ri sk of coronary heart di sease (CHD) be tween the popul ati on quintil es with the hi ghest a nd lowes t
trans fat consumpti on was 1.50 (1. 12-2.00 95% co nfide nce inte rval)6 . Ascheri o e t al de monstrated a relati ve ri sk of
7
2.44 ( 1.42-4. 19) in a smaller, non-gende r-restri cted tud y conducted in Bo to n . These re ults demon trate
ubstanti al increa es in CHD related to hi gh trans fat intake. Other studi e have examined the impact of tran fat s on
known ri sk factors for CHD. TFAs in the di et have been shown to both lower erum HDL and raise LDL
c ho lesterol, both indepe ndent ri sk fac tors for CHD. These effec ts on serum lipids are seen in both me n and wome n8 .
Despite these data, fat re main a maj or source of calori es for many people. People often find it diffi c ult to
co mpl etely e liminate a source of ca lori es from their di et; they are more likely to replace a ource of ca lori es with
other food that prov ide similar caloric intake . So, it i instruc ti ve to compare the health ri sk posed by tran fats to
those of similar compounds with which they mi ght be repl aced .
Repl acing T FA with any other ca lorie source has been shown to reduce levels of LDL, or " bad
cholesterol" 2•3 . Reduced LDL levels decrea e ri k for CHD. Studies have al o demonstrated that repl ac ing TFA
with other fats increase serum HDL levels. Low HDL leve ls have also been linked with cerebrovasc ular and arterial
di ease, o eliminati on of TFA from the die t may al so reduce the ri sk of the e di eases. In a diet in which TFAs
provide 2% of calori es, replacing the calori es from TFAs with an equal mix of carbohydrates, aturated , mono- and
polyun aturated fat , reduces the incide nce of CHD by 3.8%. If the TFAs are replaced by an equal mi xture of mono
and polyun saturated fats, the reducti on is 5.4% 9.
Epidemiologic tudi e , however, have sugge ted a stronger reducti on in heart disease if TFA are
e liminated from the di et. Repl aceme nt o f TFAs by equal parts carbohydrates, aturated , non-TFA mono- and
po lyunsaturated fats has been estimated epide mi o log icall y to co nfer a ri sk reducti on of over 25 %. It is like ly th at the
true ri k reducti on fall s so mewhere in betwee n these estimate , which would indi cate a signifi cant ri sk reduc ti on
9
from elimination of dietary TFAs .
Some recent calcul ati on suggest that significant reducti ons in TFA levels in the United State could
preve nt between 72,000 and 228 ,000 cases o f heart di ease a year, or up to 19% of the total annual incide nce 2.
Reduc tio n or e liminati on of TFAs would go a long way to reduci ng a very signifi cant cause of morbidity and
mortality.

Policy Implementation
Efforts to ban indu tri ally produced TFAs in food have been widely covered in the media. Recent pre s
coverage in North America ha foc used on the ac ti on o f Ne w York City ' muni cipal governme nt, which instituted a
ban on TFA in 2006. But New York 's effort is only one in a long string of initiati ves aimed at curbin g people'
intake of tra ns fats. Similar actions have been undertaken around the world , and have used different techniques to
achieve different result .
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The m t common path to reducing TFA consumption ha been throug h government regul ati o n of the/ood
industry. In re pon e to Will e tt et al. 's 1993 Lancet paper demo nstrating the adverse health e ffects of TFAs , the
10
Dani h Nutriti on Council e mbarked o n an ex te n ive rru ssion investi gate these effects furth er . In a series of reports
the subj ect, they demo n trated the wide body o f data that had arisen demo nstrating the adve rse health e ffects ?f
TFAs, such as increased CHD inc ide nce, and the absence of health bene fits. They conc luded that TFA u ed 1.11
indu tri a l and bakj ng proce ses are respo n ibl e for the majority o f Dani h TFA cons umpti o n, and ad vocated for thelf
e lirrun ati o n from the food uppl y 11.1 2 The Council led a long camprug n again t industrial TFAs, in response to
10
which the governme nt of Denmark e nac ted the world 's ftrst nati on-wide TFA regulati on in 2003 . The Canadian
Ho use o f Conuno ns considered a simil ar measure in 2004, but the bill fai led when parliame nt was dissolved prior to
the genera l e lec ti o n of that year. Despite the failure of that bill , the issue co ntinued to ma ke waves at all level of
government in Ca nada. A 2006 report by the federal Tran Fat Ta k Force reco mme nded lirruting trans fat conte nt to
13
two percent of total fat in preadab le margarine and fi ve percent of tota l fat in a ll o ther foods . At the muni cipa l
leve l, Toronto 's med ical offi cer o f hea lth , Dr. David M cKeown, is chedul ed to iss ue a report by September 2007 on
possible strategie. for eliminating trans fats in the c ity 14 .
.
f . k 15
M o nitors in Denmark have verified th at the legislati ve efforts have succeeded in reduc mg trans at mta e
As the effort is ti II frurly recent, no lo ng term tudi es have yet tudi ed whether the effort have yie lded sub tanti al
publi c hea lth benefit. Co ntinued mo nitoring and follow up of TFA red uction effort mu t been undertake n to
determine whether the effort has prevented C HD in the Dani sh population .
In a parallel ucce to th at seen in De nmark, the food industry in The Netherl and achieved a ig nificant
red ucti on in tran fats in their nati o n's food uppl y, without need for governme nt interventi o n. A maj or tipping point
came from a 1990 publi cati o n by Korver and Katan ai ded by the Anglo-Dutc h food corporati on Unilever. The tudy
demon strated that TFA lowered HDL and ra i ed LDL leve l in the blood . After media reports di seminated thi
knowledge, Unilever deci ded in J 994 to remove TFAs from it commerc ia l pread , such a margarine. Sen ing a
hi ft in the market toward hea lthi er products and seeing one of the industry leaders takj ng uch a step, other
compani e. fo ll owed Unilever 's lead 16. Within two year of U nilever ' deci io n, most retrul margarine old in The
Netherland s contained onl y trace amount o f TFA. In 2004, another indu try- led initi ati ve ucce fully reduced the
amount of TFA in fryi ng oil used by c ha in re taurant . One estimate place the number of myocardial infarcti o ns
avoided by the Dutch initi ati ve at 1,750 cases per year 9 .
Laws uits again st corporati o n have al o been u ed to red uce compani e ' use of tran fat . The effort o f a
gro up in California call ed BanTransFats.com, Inc. led Kraft to e liminate trans fat from Oreo cookjes and to reduce
or e lirrun ated TFAs from over 600 other product . The group al o appli ed pre s ure o n McDo na ld ' in 2003 , forcin g
the company to publi cize th at it had no t c hanged it cookj ng o il to o ne lower in trans fat and continues to work to
achi eve further red ucti on in conunercial TFA use 17 .
Discussion
The Dani sh and Dutch ex peri e nces de mo nstrate public receptivene to red ucti o n of TFAs in food. They
a lso illustrate co ntrasting strateg ies for achieving thi s goa l. One rrught , the n, consider which approac h i more
suitable for Nortb America. Kala n suggest that the Dutch appr ac h may not be a exportab le to o ther countrie a it
may initi all y eem. The Dutc h ad here to a traditional me thod for crafti ng oc ial o luti o n without government
interference, derived from thei r co ll abo rati ve approac h to water manageme nt. Thi s etho ha tran lated to other areas
of Dutch soc iety; labour connic ts and other i . ues are typica ll y ettl ed thro ugh negotiati o n, rather than legi lation o r
arbitrati o n9 .
Th o ugh lackj ng the Dutch co ll aborative traditi o n, North America has lo ng u ed marke t forces to advance
soc ietal change. A market-based so luti o n may well be the be t path toward TFA red uc ti o n in Canada and the United
State . A major driving force in the Dutch ex perie nce wa the deci io n by indu try leader Unilever to reduce TFA
in thei r prod ucts. Co mpe titors e n ed thi hi ft in the market and followed uit, le t Unilever further inc rea e the ir
market share at the expe nse f the competiti on. 1f a maj or North American corporati o n were t e liminate TFA it
could start a simi lar cascade through the food indu try and ca use the same result as in The Ne therlands with ~ut
governme nt interventi on.
North Ameri can corporati on have thus far been unwilling to c hange their pra ti ce . A maj or problem
co mmo nl y c ited by North American manufacture r. is that oybean o il , the maj or edibl e oil u ed in North America
contain s alpha- lin oleic ac id , which is unstabl e and thus must be parti a lly hydrogenated to make it suitabl e fo;
cookj ng. Kalan points to McDona ld 's as e mbl e matic o f thi s res i tance; the compan y has yet to reduce TFA leve l in
the cookj ng oil u ed in their North American franchi ses, despite the chain' uccessfu ll y reduc ing TFA leve ls in
8
their Dutch restaurants . Tho ugh acti on from publi c- interest group did cause M c D nald 's to admit to thi s re i Lance
and publi c ize the TFA co ntent fit cookj ng o il , the activity ha not yet cau ed McDonald ' to adopt ingredie nt
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lo we r in tra ns fats . Pe rh aps the publi pre sure to reduce T FA conte nt in No rth America has no t ye t reac hed the
leve ls een in The Ne the rl and s in the 1990's. However, given the recent med ia coverage given to TFAs, inc reased
sc ie ntifi c know ledge of the ri sk of T FAs, the Tra ns Fat T a k Force ' s recommend ati o ns a nd O r. Mc Keown '
fo rthco min g report, Canadi a n publi c support fo r TFA reducti o n co ul d be ex pected to ba ll oon in the near future. A
maj or publi c outcry coul d create the market forces necessary for a n indu try-w id e shi ft imjl ar to the o ne see n in
The Netherl ands.
O n the o the r hand , De nmark ha ac hi eved simil ar success to T he Netherl ands by leg islating TFA level
down ward . Both the T FA- limiting bill introduced into in the Ho u e of Commo n and the governme nt of New Yo rk
C ity' rece nt decree de mo n trate that No rth Ameri can policy- ma kers favour leg islating TFA leve ls, rather tha n
waiting for indu try to make a change in their practice that mi ght never happe n.
The Ameri can Food and Drug Admini trati o n has alread y required th at tra n fa t conte nt be inc luded o n
food labe l , and it Nutriti o n S ub o mm.ittee of the F od Ad vi ory Comm.itt e concluded that tra ns fa t are " more
ad verse" than sa turated fats in te rms of increa ed ri sk o f coro nary heart disease 18• A me nti o ned prev io usly, the
newe t editi o n of Canada' Food G uide, published in 2007 , specifi call y cauti o ns that tran fats ho ul d be avo ided as
much as po sible. The e may be een a first steps toward s furth er regul ati o n o f T FA levels in food , th o ug h firm
legi lati o n o n a nati o nal leve l has not been considered since the fail ed 2004 Co mmo ns bill.
Gi ven the lack o f industry-dri ven change seen in North Ameri ca to date, governme nts co uld be persuaded
to introduce hard hitting legislati o n if pro mpted to by the publi c. Some success has a lread y bee n . hown by
17
BanTra nsFat. com, Inc., th o ug h wide pread reductio n of TFAs have no t yet been achieved through liti gati o n .
Increased public aware ness o f T FAs coupled with failure of marke t fo rces or legislati on mi ght lead to uccessful
lawsuit achi ev ing dramatic reduc ti ons in TFA co nte nt in the future.

Conclusion
The health ri k po ed by co n umpti o n o f trans fats are we ll doc ume nted . Increa ed level of erum LDL
and lowered HDL increase o ne's usceptibility to coro nary heart disea e and other probl ems. Re pl ac ing tra ns fat
conte nt in food with a combinati on o f other types o f fat prov ides substanti al reducti o n in ri k o f coro nary heart
disease, a nd some studie suggest that up to 19% of coronary heart di sease case could be prevented through TFA
reducti o n initi ati ve .
As Ca nadi ans become mo re aware of the ri sk posed by TFA consumpti o n and the altern ati ves to eatin g it,
they may demand a reducti o n in TFA levels in their food. Whether market forces, government legi lati o n or lega l
acti o n dri ve thi change re ma in s to be seen, but reducti o n ofTFA to levels similar to those seen in De nmark and The
Netherl a nd will likely be a reality in the near future.
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Thinking on our Feet
A Clinical Perspective on Colorectal Cancer
Amber Mene;.es, Meds 2009

Case
Mr. P . Smi th is a 60 year-o ld gentle man who presented to hi fami ly ph ys ician
complaining o f a ix week hi tory o f abdominal cramping and too ls strea ked with
bl ood. He a t o me nti oned tha t hi bowel hab its had changed , with increasing
constipation.
Upon obtaining a patient hi tory, Mr. Smith 's phy ic ian noted a di e t hi gh in
red meat and 40 years of tobacco u e. No fam.i ly hi story of large-bowe l di ease was
present. A digital rec tal exam was norma l, but the fecal occ ult blood te t tested gui ac
positive. After referral to gastroenterology, a colonoscopy was perfom1ed, and a lesion
was identified in the di stal colon. Pathology revealed an[JMH 2] adenocarcin oma of the
co lon.

This article has been reviewed by Dr. John Howa rd.

Introduction
Co lorectal cancer is the commonest cancer in males and females co mbined . In the developed world , thi s
di ease i second onl y to lung cancer for new cases that occur each year. 1[JMH3] Annually , there are approximate ly
130 000 case a nd 57 000 death in the US due to colorectal cancer.' The incidence of co lorec tal cancer ran ges
1
2
between the ages of 40 to 75 , although it most comm onl y arises in individuals over the age of 50.
Regardl es of eti o logy, the majority of co lorectal cancers are due to tran formation of tubular or vi ll ous
adenomatous polyps (protrusion of ti ssue above the mucosa).1.2.3 Adenomatou polyps have the potential to be
malignant, e peciall y if they are >2cm, ess il e (fl at-ba ed), and vi ll ous (papi ll ary) in nature. 2 ·3 However, <1 % of
2
polyps ever develop into cancer.
There are several ri sk factors that predispose to colorectal cancer. The e include age (after age 50), diet,
tobacco use, a history of ulcerati ve co liti and hered itary causes. 2.4 Die ts hi gh in animal fa t a nd calorie , suc h as
found when ingesting red meat and processed meat are implicated in increasing the risk of th.i s di sease. 2 Alth ough
the exact mechan.i m is unknown, 1 one possible hypothesis is that eating an.imal fat leads to greater number of
anaerobe in the gut, and their ubseq ue nt action on bile acids forms carcinogens. 2 Another lifestyle fac tor linked to
development of co lorectal cancer is cigarette smok.ing, parti cul arl y after a smok.ing hi tory of 35 year or more. 2
There i a defin.ite gene ti c component. With no close relative affected , the ri sk of colorectal cancer is 1 in
50.3 If a n indi vidual has a first degree relative (parents, siblings, children) who has had colorectal cancer, that ri sk
increases to 1 in 17, a nd then to 1 in 10 with two fir t degree relatives affected .3 Hered itary syndrome suc h a
fami lial adenomatou polyposi s (FAP) and hereditary non-polyposis co lorecta l cancer (HNPCC) also play a role in
increasing the ri sk of cancer. FAP is an autosomal do mina nt disorder that can produce thousands of polyp in
affected individuals, uch that the ri sk of co lorectal cancer is close to 100% by age 40. 5 HNPCC in volve mutations
in genes encodi ng e nzymes in volved in DNA surveill ance; defective e nzy mes lead to lack of repair and cancerous
mutation s. 5 The important point in HNPCC i th at cancers tend to ari e de novo rather than in polyp .

Screening
A variety of screen.ing tests are avail able, yet screen.in g rates are low. A possibl e reason is that profess io nal
organ.i zati ons have not yet co me to a consensus as to wh.ich te t is the be t or most prefened .6 However, they all
6
stre s the importance of screening of eligible ad ults (ie. over age 50). According to the American Cancer Society 's
C l.ini cal Guidelines for Co lorectal Cancer Screening, the strategies reconm1e nded are a ny one of the fo ll owing: 1)
a nnual fecal occ ult blood testing (FOBT); 2) flexible sigmoidoscopy every 5 year ; 3) an nual FOBT and a fl exible
7
sigmoidoscopy every 5 years; 4) colonoscopy every 10 years.

Fecal occult blood tests
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There are evera l type of FOBT , but the mo t commonly u ed is the Haemoccult test, where gui ac filter
paper undergoe phenoli c ox idati o n in the pre e nce of he moglobin in stool. 5 Ideall y, a FOBT sho uld con i t o f thre~
eri all y obtained samp le o f too l, compl eted by the pati e nt at ho me and then mai led to the ph ysician or lab rato ry .
Utilization of thi creenin g te t has been reported to cause a 14-16% reduction in the re lative ri k o f co lorecta l
cancer mortality when performed bi e nni all y over 10 years.9•1 Furthermore, FOBT can de tect 10 m.L o f blood
lo s/day in 67 % of patient . and 20 mL or more o f blood loss/day in 80-90% of pati e nt .5 The advantage o f FOBT
are that it i inexpensive and cause the patient o nl y littl e di scomfort. 5 However, a key limitati o n of the Haemocc ull
test i that 509'< of patient wi th co lorectal ca ncer te t negative , due to the intermittent bl eedin g patte rn o f the
di ea e. 2 In add iti o n. the fal e po iti ve rate increa e by 2- 10% in o lder per o ns when sa mpl es are re hydrated (whi c h
li ghtl y increa e en itivity).

°

Flexible sigmoidoscopy
Fo ll owi ng a po itive FOBT result, a workup of the colon is rec mme nded . Flexible sigmoid o copy i
5
u ua ll y the next step a. it i quick, safe, simpl e, and ha hi gh e nsiti vity and pec ifi c ity. Thi s te t is perfo rmed
5
wi th out sedation in a patient th at has rece ived a laxati ve or an e ne ma, and exa mine the di ta l 65 em of the co lo n. ·
Unfortunately, thi doe leave the prox imal ha lf o f the large bowel unexamined , yet thi limitati o n may no t be
cri ti cal. Evidence show that adeno mas of the di ta l o lon are more like ly to progre to mali gnancy than those
located in the proximal co lon.5
Colonoscopy
A trai ned endo cop i t exami nes the entire co lo n via thi s proced ure , whic h require patient to undergo light
edati on and follow a liquid diet with u e of laxati ve beforehand . During the procedure polyp and earl y cancer
can be removed .8 Colono c py i the co lorecta l cancer reening te t with the hi ghe t e n itivity and pecificity, but
that doe no t make it the best te t. 6 It is ex tre me ly ex pe n ive (the median c harge for co l no copy in Canada i $606
US dollar )6 , pose a greater ri sk of perforati o n (2 per 1000 proced ure [JMH4] , ver u 1 per 10,000 for
ig mo ido copi c procedures) and more ri sk o f compli cati on due to edative u e. 3·8 But for th o e patients without ri k
factor trying to c hoose between creenin g opti n , co lo noscopy mi g ht eem attracti ve a it o nl y needs to be
perf rmed o nce or twice in a life time. thus max imi zing compli ance. 6
As there i no ideal co ur e of action in term of cree nin g, phy ician ho uld di cu the pro and con of
eac h test in li ght of patient pre fere nce. Importantl y, the phy ic ian need to keep in mind that after the age of 50, it i
recommended that all patient. undergo so me form f creening for o lorectal cancer[JMHS] .

Clinica l Presentation
Signs and sy mpto ms vary dependin g o n the ite of the cancer. Cancer of the ri ght co lon (cecum, a cending
colo n, prox ima l tran verse co lo n) pre e nl with fatigue, weight lo s, and hypochro mi c mi crocyti c anemia. 2.3
Obstructi on or change in bowel habits is rare a the sto I are mo tl y liquid in the area o f the ri ght co lon.2 Stool
appear normal but occult blo d loss can occ ur duet ulcerati o n of le i n in the ri ght c lo n.2 In contra t, the le ft
colo n ha a maller lumen and t o l ha a e mi s lid c n i Le ney in thi area. 1
uch, a ncer of the di tal tran ver e
and de cendin g co lon te nd to ob truct pa age of l o l, cau in g abdomin a l pai n and a ltered bowe l habit
(c n tipati o n, diarrhea) .I.2.J Perfo rati o n occas io na ll y develops, with focal evere pain and te nderne . 1•2 too l appear
1
treaked with blood. La Ll y, ca ncer of the rec tum presents most co mmo nl y a bl eeding with defecation. 1 Narrowed
stoo ls, pain , and te ne mu (fee lin g o f incompl ete evac uation ) may al o be pre e nt. 1•2
Diagnosis and Management
Colono copy is per~ rmed on th o e individuals with po itive FOBT or with le ion
een
n
1
ig mo idoscopy; all lcsi n · arc then rem vcd for patho logic exa minati o n. If cancer i diag nosed on the ba i of
hi to l gy, further workup inc lude. a thoro ugh ph y ical examinati o n, abd o minal T , che t X-ray, bioche rnica l
asse. sme nt of liver fun cti n, and ro utine laboratory le ts to eva luate metastati c di ea e, anemia, and vera ll
co nditi o n.l.2 Tumour rec urre nce can be predi cted by e levation of erum carc inoembryoni c antigen (CEA) leve l .2
H wever, thi s test i not spcc i fi e, and e levated leve l are found in 709'< of pati e nt with co l recta l cancer. 1
Progn si for pati e nt with ~o l o rec ta l ca ncer is linked to the degree o f tum ur penetrati on into the bowe l wall (T ),
the prese nce of lymph node tn v lveme nl (N), and the pre ence or absence of di tant meta ta e (M ) 1 (Table 1 ).
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Table 1. Staging of and Prognosis for Colorectal Cancer 2
Sta_ge

Pathologic Desc ription

Dukes TNM

Approximate 5-Year Survival , %

Numerical

A

TlNOMO I

Cancer limited to mucosa and submucosa >90

B1

T2NOMO I

Cancer ex tend into musculari

85

Bz

T3NOMO II

Cancer ex tends into or through sero a

70-80

c

TxNlMO III

Ca ncer in vo lves regional lymph nodes

35-65

0

TxNxM1 IV

Distant metastases (i .e. , li ver, lung)

5

Ideally, curati ve urgery is attempted in 70% of patients with out metastatic di ease. 1' 3 Depending on the
ca ncer ite, surgery can co nsist o f hemico lecto my (right or left co lon), sigmoid co lectomy ( igmoid co lon), anterior
re ec ti o n (low igmoid or hi gh rectal tumours) , and abdomi no-peri neal (A-P) resecti on for low tumours in the
3
rectum. After total resection, pati ems hould be followed for 5 years with emia nnual physica l exami nati ons, yearly
blood chemi try mea ureme nts, and trienni al end oscopic survei ll ance of the large bowel ? In patients with metastatic
di ease, subsequent resecti on is sometimes attempted in otherwise health y patients with single li ver metasta es
located onl y in one hepatic lobe, no extrahepati c metastases, and have had their primary tumour already resected . 1
Chemotherapy i performed in patient with advanced co lorectal cancer. The most commonl y u ed agent i 5flu orouracil, which is usuall y admini stered with le ucovorin , a reduced folate . 11 This treatment has been fo und to
11
reduce tumour ize by 50% or more in 20% of pati ents, and prolongs median surviva l from 6 months to 11 months.
11
The mo t common ide effect are ne utrope ni a and stomatiti s. Chemotherapy also pl ays a ro le in palli ati on of
metastatic di sease, u ing newer agents such a irinotecan and oxalipl atin.3 · 11
Radiotherapy is used in rectal cancer, either pre- or post-operatively to decrease the risk of pelvic
recurrence by 20-25 ~ .2 However, it doe not appear to prolong urvival; at best, it may increase survival by 10%. 2•3
Radiati on therapy has not been found to be effective in treating primary colon cancer?
Conclusion
Colorectal cancer is a cancer that does have effec ti ve creening techniques to detect it in early or
A variety of screening opti ons are avail able, with corresponding advantages and
precancerous stages.
di sadvantages. Clinicians need to be aware of the ensiti vity and specificity of screening test when disc u sing the
di fferent options with patients. Once co lorectal cancer is diagno ed, management varies depending on the ite and
stage of the cancer, ranging from surgery to chemotherapy to rad iation.
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Zebra Files
Rare complications of common presentations in family medicine: a review of Metastatic Basal Cell
Carcinoma and Hypertension in Pregnancy secondary to Pheochromocytoma
Tiffany Kwok, Meds 2010
Badrinath Narayan, Meds2009
T he Zebra fil es secti on, with a definiti on of unusual and interesting case , at the surface
seem to contradi ct thi i ue' theme of family medi cine. However, it is important for
famil y phy icians and ge nerali sts to be aware of rare and seri ous compli cati ons of
relati vely beni gn and co mmon conditi ons so they ca n refer accordin gly. In thi s is ue
our artic le will ex plore two rare compli cati ons of two di fferent co mmon presentati ons in
famil y medi cine- metastatic basal cell carcinoma, and endoc rine hypertension in
pregnancy cau ed by pheoc hrom ocytoma.

This article has been reviewed by Dr. Nithya Romani.

PART I: METASTATIC BASAL CELL CARCINOMA

Introduction
Basal Cell Carcinoma (BCC) is the most common malignancy world wide, with a lifetime risk of 30% in
Caucas ian, North Ameri can populati ons. It is generall y an ind olent kin tumour with low metastati c potenti al and
hi gh cure rates. However, conseque nces of metastas is are often deadl y and it is important to be aware of thi s severe
compli cation.
Clinical Presentation
There are 5 main clinical subtype of BCC:
1) Nodular BCC- the most common variant presents as a firm , translucent papule or nodul e with a mooth
surface, te langiectas ia, and well -defined border . A cy tic vari ant i uncommo n.
2) U1cerating BCC- al so known a rodent ul cer, presents as an ulcerati on on the skin with a roll ed border,
translucency, smooth surface , telangiectasia, cru ting.
3) Morpheaform/Sclerosing BCC- rese mbling a superficial scar, white/yell ow waxy cleroti c plaque with
pepperish pigmentati on.
4) Superfi cial BCC- thin , erythematous plaque with telangiectasia and scaling. Usuall y multi centric.
5) Pigmented BCC- A rare variant, pre ents with bl ac k or brown mac ule uperimpo ed on features of nodul ar
BCC.
Most BCC ' s occur a an isolated single lesion on the head and neck in li ght-skinned males over 40. Differenti al
di agno is of BCC inc lude quamous cell carcin oma, actini c keratosis, sebaceous hyperplasia, dermatofib roma,
superfi cial spreading and nodul ar melano ma, and melanocytic nevi, depending on its subtype.
Table 1: Predi sposing factors for BCC
12
Skin phototypes I, II or albino with prolonged sun exposure '
1
Hi tory of heavy un ex posure in childhood
2
X-ray therapy for facial acne
Inge ti on of arseni c (Superficial multicentri c BCC)I.2
•
5
ImmunosuppressiOn
Positive famil y hi tory of skin cancer'
Genetic conditions (albinism, xeroderma pigmentosum, Bazex's syndrome, Gorlin's syndrome) 1
BCC may be treated surgically or non-surgica ll y. Surgical treatment includes electrode sicati o n and
curettage, cryosurgery, excision and M oh ' mi crographic urgery. The latter is re erved for ca es in high ri sk ite
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o n the face , morphoe ic and rec urrent tumo urs. C ure rate for surgical treatment exceed 95 %: .N~n-sur~.i5ca l
treatments are Jess effective and include radiati o n, pho todynamic therapy , and topical flu orouracil or muqUimod.

Metastasis
Metastasi is suc h a rare occ urrence that some sources even state that BCC doe no t metastasize . Ho wever,
reported rate of meta tas i ran ge between 0.0028 to 0.55 % of all BCC ' . Meta tati c BCC (MBCC) was fir t
described in 1849 by Beadl e whose 46-year old mal e patie nt had an ulcerating BCC o n the face metastasizing to the
submaxi llary lymph node. 3 In 195 1, Latte et. al. described criteri a for MBCC (T abl e 2):
Table 2: Lattes' criteri a for MBCC 3
Primary tumo ur ori ginated fro m the skin and no t fro m mucou membrane or other gland
Metastasis occurred to a di stant site from the primary tumour and could not result from direct extension
Both metastati c and primary tumours have ide nti ca l hi stopathology
Since 1849, the re have since been o nl y over 300 cases of MBCC reported . Many of the predi spo ing
factor for MBCC are similar to those of BCC, co mmo nl y pre e nting in li ght- kinned indi vidual s, mal es, and in the
head and neck area. BCC' have been found to me ta ta ize thro ugh both he matogeno u and lymphati c avenue ,
lymphati cs be ing more common. Common ites for me ta ta is (in order of frequency) include lymph nodes, lung ,
bones, skin and parotid glands. In von Do marus e t. al. ' review of over half of the e ca e , patients first developed
4
BCC at a medi an age o f 45, and later presented with MB CC at a medi an age of 59. Thi i hi gher than that of BCC,
and pos ible expl anati o ns inc lude inherent aggressiveness of earli er-presenting BCC. or older patie nts may no t
urvive to metastas is.3 Medi an time from start of BCC to progres io n to MB CC wa found to be 9- 11 years, but
interval range from mo nth to decades. 3 Prognos is of MBCC is poor, with a medi an urvival of 8-14 month after
4
its di agnos i , and a 5-year urviva l rate of 10%.3·
4

Tabl e 3: BCC at hi gh ri sk for metastasis3•
Located on head and nec k
Size >lOcm
Deepl y penetrating tumo urs
Perineural spread
In vas io n o f bl o d ves e ls
Multiple recurrences in primary tumour site
Mor heaform and adeno y. ti c ubty e
Workup fo r pati ent with uspected MBCC co n i t of hi tory and phy ical examinati o n, conce ntratin g on
lymph nodes near the primary BCC. Helpful lab te. ts inc lude CBC, li ver fun cti o n, bo ne can, and CT scan of the
chest, abdome n and pe lvi s. 4
Beca use o f the rare nature and poor prognos i o f MBCC, there i not much ev ide nce urrounding optimal
treatme nt. In ge neral, treatme nt i palli ati ve and de pe nd o n the locati on o f me ta tasi a we ll a the genera l health
and age of the pati e nt. ln case of local spread, surgery prov ide the be t progno i , whe rea radiation therapy and
chemotherapy with C i platin is best for genera li zed di ea e.~

Conclusion
Basal cell carcin o ma is an ex treme ly c mm o n ma li gnancy that is o me time treated by fa mily physicians
due to ease o f treatme nt, however, know ledge o f it deadl y me tastati c po te nti a l is crucial to prompt re ferral ,
treatment and poss ibl y better prognosis for the pati e nt.

PART II: HYPERTENSION CAUSED BY A PHEOCHROMOCYTOMA AND IT'S MANIFESTATION IN
PREGNANCY
Introduction
Hyperte nsio n is a frequent complicati o n o f pregnancy and may compro mi se fetal and maternal o utcome .
Hyperte n ion may be pregnancy- induced, e . enti a! r econdary to endocrine di orders. M o t cases o f endo rine
3
hyperte nsion are the con equence of adrenal di sea es. In o ne ca e in the literature, a pregnant femal e who has been
- 30-
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suffering from persiste nt hypertension arri ves at her fa nlil y ph ys icia n co mpl ainin g o f a headache. T he pa ti e nt is a
recent immi grant to Canada a nd does not spea k English very well. T he results o f the test made d uring th at vi it fi nd
that the pa ti e nt ha a co nste ll ati on of negati ve sign and ymptoms: pe rs iste nt hype n e n ion, hyperre nexia, ede ma,
proteinuri a, o liguri a, hyperuricenli a and thrombocytopeni a. T he fa nlil y doctor uspects preec la mpsia. However, in
1
thi case the pati e nt was eventuall y found to have a very rare co nditi on ca ll ed a pheochromocytoma.
The mo t hazardous fo rm of e nd oc rine hypertension durin g pregnancy is a pheochromocytoma because it
may in volve paroxy mal arrh ythmi a and/or hyperte nsion durin g la bor. 3 It is therefore importa nt th at it be d iagnosed
early during the pregnancy to reduce mortality and morbidity to the mother and the baby. D iag nos i i diffic ult
however because a preg nant woma n can present so lely with chronic hyperte n ion a nd headaches, whi ch can lead
one on the path to su pect preec la mp ia or e enti a t hyperte n ion. In th e case tudy, as the a uthor me nti on. the
1
wor e ning headac he a nd la bile hyperte n ion co uld also be attributed to stre s, c ultural iso lati on and med icati o n.

Natural History
A pheochromocytoma is rare, found in about .0 1-. 1% of pati ent with hyperte n io n in the ge neral
4
popul ati on. The re are onl y about 200 ca e reported of it occ urring in preg nancy. T hey are catecholanline
sec re ting tumours of the adre nal medull a 's c hromaffin cell s (of ne ural ere 1 origin and secre ting epinephrine,
norpeinephrine and dopanlin e ). They can occ ur at all ages in both sexes. but should e peciall y be suspected in
pati e nt presenting with poorl y co ntrolled hypertension at less than 40 years o f age.
In pregna ncy, the matern al mortality rate is 2-4% if tumour is di agnosed in the a ntenatal peri od , and I 425% if di agnosed intrapartum or afte r delivery. 1 Fatal cri e can be caused by variou stimuli fro m anesthe ia to the
4
mechanical effect of vigorous fe tal movement to the ex pulsive forces of vaginal deli very. Fetal mortality is 11 1
15 % antenata ll y, but 55 % if during labour or a fter deli very.

Pathophysiology
They are poradic in 90% of cases and inherited in 10%. They are a soc iated with ME N , M ENnA and
1
M EN1IB syndromes. They are often described by the 10% rul e : 10% ari se in a soc iati on with fanlili al syndrome ,
10% are ex tra-adrenal , 10% in sporadic cases are bilateral, 10% are multipl e and 10% are mali gna nt. Prognosti c
fac tor for a pheochromocytoma include stage, age, hi stology, and vari ous chromosomal markers such as DNA
pl oidy, n-myc amplifi cati on, trk- a ex pre ion, 17q gain , 1p lo and te lomera e ex pres ion.

Diagnosis
Diagnosi is made by recogmzmg the e ffect of a hormonal nlilie u ca u ed by excess catec holanline
secreti on (a sympathetic response) as well as the re ulting producti on of various vasoacti ve peptides. A pati e nt can
present with a combinati on of hypertension, Headac he, Hyperhydrosis (s weatin g flu shing of the skin ), Hypomotility
of gut (co nstipati on), hyperglycenli a and hypermetabolism (tachycardi a, anxie ty, nau ea, palpitatio n ).
AI o di stingui hing is postural hypote nsion and hyperte nsion worsenin g in the supine positi on. 1 It can be
u tained or paroxysmal, and there can be a drop in orthostati c bl ood pre sure. C ia ical symptom of
pheochromocytoma can be reproduced by a n abdonlinal massage in the postpartum peri od . 1
A 24 hr urine scree n for metabolites o f catecholanlines( metane phrine , fracti onated catec holanlines and
vanill ylmandeli c acid) is the common creening te t. A pi a ma screen can also be done for catecho lanline or
me ta ne phrines. T wo normal test of pl as ma a nd urine catecholanlines can exc lude a di agnosis. Te ts fo r tumor
locati on are linlited to ultra o und and magneti c resonance scans in order to avoid maternal a nd fetal irradi ati on.3

Differential
Other co nditi ons whi ch increa e catec holamines include anxie ty, pain , bl adder di te nti on, trauma and
pressure on the tumor. Cardi omyopath y has been reported as a co mpli cati on o f a pheochro moctyoma in pregnancy.
1
CHF can increase pl asma and urine me tane phrine levels.

Management
The patie nt i managed by the family ph ysician in tande m with consta nt ob tetri cal mo nitorin 0o a nd a
prompt e ndocrinologist referral. While re ferral to a surgeon for excision o f tumour is the de finiti ve c ure, clini ca ll y it
i till controversial as to whe n it can be safely used' . Ex pert do agree however that diagnosis in later pregna ncy is
best handled with medical stabili zati on.
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Alpha blockade should a lways be established before before ~- If ~-adrenerg i c bl ockade is attempted first
to red uce blood pre sure by reducing heart rate a nd co ntractility, it will also result in the loss of vasodilation caused
by ~2 receptors. There will be an increased alpha effec t that is unopposed by ~2, and will thus have further increased
the blood press ure. The alpha blocker of choice is phenoxy-benzam.ine. 4

Conclusion
A pheochromocytoma is a rare yet hazardous form of endocrine hyperte nsion during pregnancy which a
physician should be vigi lant for in patients with poorly controll ed hypertension and a constell ation of signs a nd
symptoms which point to a adrenergic hormo nal mili eu. Medical stabilizati on, prompt referra l and considerati o n of
surgery are th e compone nts of proper management.
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Feature Article
Annular Papules: Making the Right Diagnosis
Mohamed Alarakhia, Meds 2008
A nnular papules or pl aques are frequ entl y e ncountered by Famil y Phys icians. Tinea
corpori s is often the first entity that come to mind beca use it is common and it
class icall y pre ents with thj s morphology. However, there are o ther important dj agnoses
that need to be con idered . For exampl e, granul oma annul are is characterized by
erythematous or tle h-coloured pl aques with smooth borders and no scaling or vesicles.
The les ion of nummul ar dermatiti s are coin shapped papul es with central vesic les that
expand and cau e a central cl earing. Subacute c utaneo us lupus erythem atosus can
prese nt with bright red annul ar lesio ns with central regress ion and littl e caling. Fi xed
drug eruptions appear as we ll de marcated pl aques that can develop central vesic les or
bull a. Thi s arti cle will revi ew the e co nditi ons.

This article has been reviewed by Dr. Firas Al-Dhaher.

Introduction
Examining the morphology of skin lesio ns is critica l when worki ng towards a diagnosis. H owever, o ne
must be care ful not to link a specifi c morphology with a single e ntity. A nnular papule or pl aques are quite di stinct,
but they can also be very deceptive. These ringed lesions immedi ate ly pro mpt both patie nts and physicians to think
o f "ringworm" or more correctly tin ea corpori s. The term "ringworm" i a mi nomer fro m a time whe n suc h raised
1
ringed lesions were be lie ved to be caused by in vasive worms. The associati on between annular lesio ns and tinea
corpori s can lead to a delay in the diagnosi and treatme nt of many of the other lesions that can present as annular
papul es or pl aques (T abl es 1 and 2). Thi s arti cle will review tinea corpori s, granulo ma a nnulare, nununular
dermatiti s, subac ute cutaneous lupus erythematosus, and fi xed drug erupti on

Differential Diagnosis of Annular Papules or Plaques
Infections: Tinea Corpori s
lnfl anunatory: Granul o ma Annul are
Dermatitis: Nummul ar
Drugs: Fixed Drug E rupti on
Auto inunune: Subac ute C utaneous Lupu Erythemato us

Table 1. The Differential Diagnosis of Annual Papules or Plaques.

* note: The diffe renti a l di agnos is of annul ar les ions i vast. Onl y annul ar papule and pl aques were reviewed in
thi s arti c le and even these e ntiti es were limited to tho e deemed suita bl e for an initi al differe ntial diagno is.
Images
Images for the lesions presented in thi s arti c le (with the excepti o n of nununul ar dermatiti s) can be vi e wed at:
http://www .atl asdermato logico.com.br/
The pi c ture number and names are indi cated be low:
Tinea Corpori s
5600 . Tin ea Corpori s2
5597. Tinea Corpori s l7
Granul oma Annul are
1771 . Granul o ma A nnul are I
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1794. Granuloma Annul are6
Nummul ar Dermatiti s
http://www.lib.ui owa.ed u/h ardin/md/pi c tures22/dermne tleczema_nummul arecz0530053.jpg
Fixed Dru g Erupti o n
1628 . Fixed Erupti on
Subacute C uta neous Lupus Erythematos us
3 190. Lupu Erythemato u - ubac ute C utaneo u Lupu
(le ion under latera l aspect of left eye)

rythematosu 2

Tinea Corporis
Tinea corpori s is the most co mmo n cause of annular le ion in adults.' It is a de rmatophyte infecti on that is
2
commonl y caused by Trichophyton rubrum and Trichophyton tonsurans in the Uni ted States and Ca nada. An
3
indi vidual ca n be infected by co ntac t with infec ted persons, animal , or oil.
45
There are o fte n multiple e rythe matous sca ly papul e or plaque that have an _active border.
They may
grad uall y e nlarge over time and pread centrifuga ll y from the po int of kin invasion. Lesions may be a ociated
wi th ve icle . There may al o be burning a nd pruritus . ~ The typ ical distribution include the trunk and extremi tie
4
exc luding the nail , palm , so le , a nd gro in . •5 The di agno i is clinical a nd treatment i with topi cal antifun gal uch
3
35
a c lotrimazole, mi co nazo le or terbinafi ne. • If resi tant to top ica l the rapy, systemic antifun gals can be used .
Granuloma Annulare
Granuloma Annulare is a comm on asympto mati c cutaneou conditi on o f unkn own eti o logy. The le ions are
6
erythematou or tl e h-colored non- ca ly papule .6 The papul e. group together forming an annul ar arrangement. In
contra t to tinea corpori , there are no as ·ociated ve icl e and the annular border i mooth with no sca ling.' Lesions
7
can be found anywhere on the body, and are most commonl y een on the legs and the dor um of the hand and feet
Often the palms, sole , and calp are pared . The di agnosis o f gruanul oma annulare i clini cal. 6 A punc h biopsy is
done if there is any uncertainty about the di agno is. 6 Becau e granul oma annulare i elf limited and re o lves
7
pontaneou ly in more than 50~ of patient in two month s to two years, no treatme nt in required. However,
patient often find the les ion di stressing; thus, for cosme tic purpose or in ca e where the conditi on i more
chroni c, topical glucocorticoid are the first line o f therapy. 7 Intrales ional corticosteroid inj ecti ons, cryotherapy, a nd
electrodesiccati on are other opti ons.6 Littl e ev ide nce has been accumulated on the effi cacy of treatment opti on for
di seminated granuloma annulare. Dap one, i otre tin oin , hydroxycho lorquine, and PUV A (p oralen and ultrav io let
A) have been used with some ucce in mall unco ntroll ed tudies a nd ca e re port , but consultati o n wi th a
6
Dermato log i t should be sought at thi stage.
Nummular Dermatitis
Nummular dermatiti s i a di e minated eczema that is characteri zed by well demarcated co in - haped
8
papule and plaques. Central ve icles may form , which the n expa nd and cau e a central clearing.' The latter
phe nomenon results in an annul ar appearance.' The le ion ca n be assoc iated with pruritu , xeros i , and contact
58
e n iti zati on (e.g. ni cke l, chromate, fragrance , etc.). ' Nurrunul ar dermatitis commonl y affect the ex tremiti e and
1 8
ofte n fo llows a very ctyoni c cour e. ' The diagnosis is clinical and the treatme nt i with medium to hi gh pote ncy
topi ca l corti costeroid .)
Fixed Drug Eruptions
Fixed Drug Erupti ons (FOE) generally occ ur l -2 week after the fir t expo ure to a drug .5 Sub eq ue ntl y,
5
le ion develop over the cour e of 24 hour . There are ca e report that dem n tra te FOE with most of the
commonl y used drug including ulfonamide , NSAID , barbituates, tetracyc lines, and carbe mazepine. 5 · 9 One or a
few round , harpl y demarcated, erythe matou or pi gmented pl aque typi ca ll y appear. They may became edematous
10
or form vesicles or bulla. The ve icl e or bulla are often central giving the appearance o f an a nnular lesion. In
5
additi o n, an erosion can deve lop in the middle of the le ion. Le ions can occur a nywhe re in the body, but ofte n
5 9
favour the lips, face, hand , feet and genitalia. '
They fade over several day ofte n leav ing an area of
9
hyperpi gme ntation . There i al o a variant of FDE that i non-pi gme nting . 11 When the cau alive druo is
.
b
readmini te red the leswns reoccur exactly on the arne ites, which is a di tinguishing feature of FOE. 10 Additional
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lesion may also appear o n readm.in.i trati o n. 10 Di agnosis is based o n hi story and patch or provocati o n testwg.
12
T opi cal appli cati on of increas ing co nce ntrati o n o f drug will illic it the reac ti o n in many pati ents. Co n! ro lled oral
exposure to the drug is attempted if topi cal testing is negati ve and the drug is still stro ngly uspec ted. The maw
treatme nt is eliminati on o f the offe nding agent. 9

Subacute Cutaneous Lupus Erythematosus
Subac ute c utaneo u
lupu s erythe matos us (SCLE) prese nts as either annul ar or psori as ifo rm
3
•
I.
t4
papul osquamo us le io ns.' The annul ar les io ns are bri ght red with central regressio n and httle sea w g.
Ph otose nsiti vity is a significant compo nent of SCLE. Thus lesions commo nl y appear o n the ex tensor surface of the
t3 L
·
arm , do rsal s urface of the hand , upper bac k, the V -nec k area o f the upper che t, and the houlders.
e JOn
13
re o lve with light atrophy (no earring) and hypopi gmentati on. Di agnosi is ba ed on clini cal findin gs and
confirmed by hi to logy and immun opath ology. 13 Approx.i mately 50% o f pati e nts with SCLE will ati sfy fo ur or
more of the Ameri can Rh eumati sm A soc iati o n's criteria for systern.i c lupus erythematos us.' Using
immun opathologica l te ting, immunoglo bulin and/or compl eme nt compo ne nts ca n be shown to fo rm a granular
15
band- like array at the dermal-epidem1al juncti o n in 60% of SCLE pati e nts. F urthermore , a di tincti ve "du t-like"
pattern o f l gG depo iti on overl yin g epiderma l ba al ce ll s and cell just below the dermal-epidermal junc ti o n was
reported t be an frequent marker for SC LE le io ns. 15 In terms of sero logy, 70 % o f these pati ent are ANA po itive,
whil e 63 o/t have Ro antibodi e . 14 • 16 The first tep in treatme nt is avo id ance o f ex posure to unlight by using
un creens or phy ical barri ers. Topi cal or lntralesional corti costeroid , tacrolimus, or pimecro limus would be the
19
nex t step. 17· 18 Most pati ents will go on to require so me fo rm of syste rn.i c therapy. Approximate ly 75 % of SCLE
pati ents res~o nd to sing le agent or combinati on am.in oquino line therapy (hydroxychl oroquine, chl oroquine ,
quinicrine). 1 For those who fa il antimalari a l therapy o ther opti o ns inc lude d ap o ne, th alido m.ide, c lofazarn.ine, gold
13
fo rmul ati on , and methotrexate.

Conclusion
Formul ating a good differe nti al di agno i of annul ar papul es a nd pl aque is an importa nt te p in reducing
the te ndency to labe l all annul ar lesio n a " ringworm". It will he lp fac ilitate the appropri ate in vesti gati o ns and
management of the e varied conditi o ns.
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Feature Article
Preventive Care Strategies in the Management of Systemic Lupus Erythematosus
Tiffany Kwok, Meds 2010
Stephen Chihrin, Meds 2008
Sy te mic Lupus Erythematosus (SLE) is o ne of the mo t common yet complex
autoimmune connecti ve ti ssue di sease . The c lini ca l pi cture painted by SLE is broad ,
affec ting muscul o keletal , ski n, cardi ovascul ar, re nal and centra l nervous system , and
thu pre e nts a c hall e nge for any physic ian to manage . One of the most impo rtant roles
for a family phy ician in the care of thi s pati ent i to focu o n preventi ve measures to
minimize co mpli cati on from SLE thereby improv ing qu ality of life. Thi article aims
to review the commo n presentati o ns and co mpli cati o ns arising from SLE and the
corresponding po sibiliti es for a preventi ve care approach.

This article has been reviewed by Dr. Georg e Kim .
Introduction
Systemic lupus erythematosu (S LE) is a complex a uto immune connecti ve ti sue di order not uncommo nl y
encountered in general practi ce. SLE ha a preva lence of nearl y 30 per 100,000 pati ents, and is sig nificant for its
frequency in younger female , occ urring nearly nine time a often in women , with onset most often during the 2"d
to 4th decade of life. 1. 2 A pati ent with SLE poses numero us lo ng- term chall enge to the primary care physician , with
potenti al for ac ute life threatening multi-syste m organ di ea e a well a chro nic debilitation resulting direc tl y from
the di sease itse lf or secondary to medi cal management. The predi po ing and precipitating factors underlyin g SLE
are not well under tood, but are be lieved to inc lude genetic and e nviro nme ntal tri gger re ulting in dysregul ati o n of
both innate and adapti ve inm1Une mechani m a well as impa ired c learance of immun ogeni c complexes inc luding
4
apoptotic cell s. 3· The diffi culty in understanding the e mechani m , their interacti on, and their own e tiol ogies
currentl y prec lude primary preventi o n. A such, SLE mu t be aggre ively managed following di agnos is to
minimi ze ongoing compli cati on ri sk. Thi s paper aim to address a number of area in which preventive medicine
can greatl y improve the quality o f life o f indi vi dual with SLE, and potentially reduce lo ng-term morbidity.
Diagnosis
The American Co ll e~e of Rheumato logy ha establi shed di agno tic criteria, quite familiar to the medical
tudent, as shown in Table 1. Intended for re earch c ia ifi cati o n, the e criteri a provide a n overview of potential
signs and ymptom but h uld not be relied upon for indi vidua l diagno i . The complexi ty of these criteria
illustrates the considerabl e variability of SLE and the diffic ulty comm nl y encountered in reachin g a diagnos i . In
fact, it ha bee11 . uggested that mo t pati ent receive a di agno i nearly five years following initi al onset of
ympto m .6
The most commo n initi al manife Lati o ns inc lude mal aise, fatigue, nau ea a nd anorexia. 2 A low grade fever ,
photo e n iti ve rashes, pleuritic che t pain , compl aint of xerosto mi a or xero ptha lmia, hair lo s, or s udde n and
persi te nt arthralgia may a l o appear early in the di sea e and are more conuno nl y the reason fo r initial pre e ntation
2
to the genera l practiti one r.
Selec t laboratory di agnosis may be initiated pri or to pecialist referral and can
demonstrate pos iti ve anti -nuc lear antibodie , as well as antibodie to do ubl e- tranded DNA. 1 Classically, ESR
appears elevated in the absence of an e levated C RP . Additiona l laboratory inve li gati o n completed during initial
work up may also revea l anemia or signs of li ver or kidney impairment. Additi o nal antibody screens, genera ll y
initi ated by a rheumatologist, may inc lude anti-ENA, Ro, La, RNP, or Sm. 1•2
Principles of Management
Manageme nt of SLE is generally initi ated by a spec ia li t and the n continued cooperatively be tween
pecialist and the primary care provider, and in no n life-threate ning ca e co nsist primarily of symptomati c
management. To thi s purpose, analge ic and antimalaria ls are freque ntly e mpl oyed. Acetaminophen has shown
~ odes t effec tiv e n es~ in _co ntro llin ~ pain , while ~n.ti~a l arial such a . hydroxychl oroquine are uccessful in reducin g
tnfl ammatJ on re ul~tn g tn arthral g 1 ~ and dennalltJ . Thes_e therap1es ~ave also been associated with significantly
lower level of pati e nt reported faLJgue and frequency of d1 ea e flares. It ho uld be noted that non- teroida l anti -
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infl ammatory drug (NSAIDs) are re latively contraindicated in the treatment of SLE secondary to the numerous
co mpli cati ons of SLE that may be exacerbated by NSAID therapy, inc ludin g acce lerated athero c lero is, nephriti ,
and a ep ti c menin giti .2•6
Life threateni ng flare of SLE, including ac ute lupus ne phriti s, often require in pat ient initiation of hi gh
inc lud in g cyc lop hospharrude or
dose glucocorti co ids in combinati on with immunosuppre sive age nt
2
mycophenolate. Due to the diffi culty in preventing fl ares pharmaco logica ll y, and the signifi cant comorbiditie
associated with major fl ares and their treatment, there exists signifi cant potential for reduction in long-term
morbidity and mortality through preventive care.

Preventive Care
Many compli cati on may ari e from a fl are of SLE. For the purpose of thi article, we will discuss
trategies which may prevent or delay the onset of these complicati ons.
Musculoskeletal
Joint pai n i an ex tremely conunon and physically debilitating co mpli cation of SLE. Tendernes and
inflammation are fo und in a synunetric, nonero ive po lyarthriti s commonl y presenting in proximal interphalangeal
and metacarpophalangea l joints, as well a wrists and knees. 6 Care must be taken to rrunirruze tre s placed on the
joints e peciall y during heavy lifting acti vitie . Minimizing j oint stress may also improve fatigue, whi ch has al o
been pos tulated to tri gger fl are-up of SLE in ome. Additionally, exercise may reduce sti ffness and increase
7
muscle strength.
Osteoporosis and o teopeni a are reported in a many a 46% o f pati ents. Deficit in bone minera l den sity is
said to be a result of both di sease mani fes tati ons (fati g ue, j oi nt and muscle infl ammati on and pain can red uce
mobility and impair weight bearing acti vity for a given bone mass) and prolonged corti cos teroid use.
Cortico teroids are commonl y used in the treatment of SLE and increase the ri sk of osteoporosis by di sturbing
calci um homeostasis, decreasing bone formation , and decrea ing circul ati on of gonadotroph .8 Ramsey-Goldman et
al. have shown a positive associati on in women between th ose with SLE and increased bone fracture ri sk. 9
Fortunately, regul ar exercise (a rrunimum of 40 rrunutes of aerobic acti vity four time a week) ha been hown to be
7
Other preventive opti ons include smoki ng ces ati on, moderate
protecti ve of bone rruneral density Jo .
con umpti on of alcohol, adequate intake of dietary calcium and vitarrun D, and measures to prevent falls in the
elderl y. Finally, dosi ng of corti costeroids hould be constantl y monitored and eva luated to minirru ze dose whenever
po ible. 8
Skin
Photo ensiti ve skin ra hes such as di scoid lesions and malar rash affect up to 20% of pati ent with SLE and
may be earring and disfi guring. 6 Ultraviolet radi ati on i po tul ated to tri gger SLE fl are by damaging ce llul ar
material, most notably nucleic acid , and degrading them into inununogeni c co mplexe .3 •4 Patient hould be
counseled in sun avoid ance and sunscreen usage, as thi s will rrunirru ze rashe and potenti all y reduce the freq uency
1
and everity of subsequent fl ares.

Renal
Lupu nephriti s i a seri ous co nsequence of SLE, with ymptoms rangin g fro m hypertension and
protei nuri a to re nal failure. Although there are no known mea ures to acti vely prevent the on et of lupus nep hriti ,
frequent monitoring of creatinine and urine protein and ce llul ar ca ts can alert the c lini cian to renal di sea e earlier in
1
its progressio n. Strict avo id ance of NSAIDs and careful considerati on prior to use of any other potentially
nephrotoxic medicati on is required in all pati ents with SLEY

Ca rdiovascular
Cardiovascular compli cati ons such as atherosclersosi , thromboe mbolic events, pulmonary hyperte nsion,
pericarditi s and systoli c murmurs occur at higher rates in SLE pati ent than the general population. 10 Curre ntl y,
ischerruc heart disea e is a leading cause of death in SLE patient , with mean age of first myocardi al in farc ti on at 49
years (20 years before that for the general popul ati on). Additionally, Esdail e et. al. fo und that young patient with
SLE ha a 7-10 times greater ri sk of developin g cardi ovascul ar di sease than the Frarrungham ri k factor esti mate
dictate . 11 As with the general population, exerci e is shown to improve cardi ovascular outcome in SLE patie nts.
Ri sk factors contributing to development of ischerrua such a hypertension, hyperlipidemi a, di abetes mellitus and
7
sedentary lifestyle, may all in part be addressed by exercise. Other preventi ve mea ures uch as smoki ng ce sati on,
nutritio n coun eling to decrea e lipids and chole terol in the diet, di abetes educati on, and med icatio ns including
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low-do e a pirin and a stalin may he lp preve nt cardi ova cular compli cati o n . 10 • 12 Additionally, antima lari al agents
such as hydroxychl oroquine typi ca ll y used to combat joint and skin manifestations of SLE have also been sho wn to
reduce LDL-cho lesterol, tri glyceride levels and thro mboembo lic eve nt , and improve insulin resistance and
12
glycemi c co ntro l.

Central Nen ,ous Svstem
C NS cha~ge a ffect 1 2-59~ of pati e nt with SLE and m t commonl y present a intractable headache ,
memory and reaso ning difficulti es, se izure and tro ke. 1 No preventi ve strategies for headache , memory o r
cog niti ve diffi culti es have yet been reported . However, seizures and troke due to thro mboembo lic events may
be ne fit from imil ar cardi ovasc ular preventive trategies as di c ussed above.
Fatigue in SLE i a lso extreme ly co mmo n, affecting up to 80 % of patients, yet is difficult to manage, oft e n
per i tin g despite di sease tl are remi ss ion. 1•6 Altho ug h the mechani sm is largely unknown, sleep interrupti o ns are
thought to ac t as a medi ator thro ugh which SLE inc rease fati gue. Exerci e has been shown to help wi th bo th
fatigue and sleep di sturbances, as it increases capacity of the oxidati ve metabo li c pathway to suppl y e nergy. Studie
have hown positi ve as oc iati o n betwee n exerc i e and higher sleep quality, increased pati e nt reported energy and
overall well -being. 7
Preg nan cy
Pregnant women with SLE are at increased ri sk for earl y lo of pregnancy, feta l death , pre-eclampsia,
preterrn deli very, and increased maternal thrombo is. 1 Regular fo ll ow-up with a ph ysician to mo nitor bl ood lupu
anti coagul ant and anti card io lipin antibody leve l may minimi ze ri k during pregnancy, e peciall y mi carriage.
Furthermore, a recent Cochrane rev iew by Empson e L al. has shown th at unfracti o nated heparin a nd low-do e
aspirin he lp reduce pregnancy loss by 54 % in tho e with hi gh leve l of lupu anticoagul ant and anticardi o lipin
13
antibodi e .
Tabl e 1: Diagnostic Criteria for Sy temi c Lupus Erythe matos us. A pati ent demo n trating fo ur or more of the
5
following at any time in the ir hi story sho uld be suspected for SLE. Sensitivity 95 %, Specificity 75 %.
Malar Rash
Discoid Rash
Ph otosensiti vity
Ora l or Nasopharyngeal Ulcers
Hemato log ic Disorders- non-iatrogeni c leukope ni a, lymphopeni a, thro mbocy to peni a
Serositi s- pl euriti s or peri carditi s
Arthritis- no nerosive in volvement of 2 o f mo re periph eral joints
Rena l Di sease- 3+ prote in or ce llul ar casts
Ne uro logic Di sorder- se izure, psychosis
Antin uclear Antibodies
Immun o log ic Disorders- inc luding anti -ds DNA, a nti ph osph o lipid Ab , anti -Sm

Conclusion
Systemic lupus erythematosus pre e nts a number of ignifi cant manageme nt c halle nge to the ge nera l
practiti o ner and rheumato log i. t alike. The age o f on et and p tenti a l for con iderable morbidity and morta lity in a
pote nti all y very healthy pati ent otherwi e requires tri ct vigil ance to addre preventive care . trategies. As SLE
pre e nt and co ntinues to deve lop a a multi - y te rn di ease, it i use ful to rev iew each sy tern , it complicati o n ,
and po tenti al for unrea li zed preventi ve care at each foll ow up visit Thi , in conj uncti o n with appropri ate treatme nt
of compli cati ons as they arise, wi ll he lp to minimi ze di ease burde n.
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Feature Article
Patient Centered Approach to Primary Prevention (PCAPP)
Adeel Mahmood, Meds 2009
As Tommy Do uglas he lped usher in Canada 's Medicare system in 1967, it marked a
new era in Canad ian health care and o ne that went onto become o ne of definin g factors
of Canadian society. Most Canadi ans che rish the Publi c health care system and co nsider
it an extreme ly important part of Canadi an ociety. However, for as lo ng as the system
has been in pl ace there have been que ti ons about the viability of the system and forty
years since its incepti o n, we stand at a critical juncture in thj s seerrungly never e nding
debate. There is no doubt in th at we as Canadians must continue to strive towards
makj ng our syste m better so th at we ca n sta nd firm on the core values of the Canada
Health Act. In thi s essay, I aim going to uggest a Peopl e centered approach to primary
prevention (PCAPP). Thi s i a group based approach to helpin g patie nts be better
advocate of their own health . I believe that thi s program can help improve the quality
of pati ent care and be an eco nomj call y feasible approac h to Primary preventio n. This is
defi nite ly not a compl ete so luti on to the chall enges faced by the health care system.
However, as the proverb goes: Little drops of water, littl e drops of sand , make the
rrughty ocean and the rrughty land . This brief essay o nl y proposes a step forward in
reaching our goal of bein g a more pati ent centered health care system.

This article has been reviewed by Dr. David Rosen.

The Backdrop
Before I go onto di scuss my proposal in any great le ngth , a littl e bit of hj storical context wi ll be helpful.
The topic of health care has been studied exte nsive ly and some even go o n to say th at it has been studied to death.
There ha been a large in vestment of mo ney, time and resources to find ways in whjch o ur syste m can be improved .
Maj or reviews such as the Mazankowskj report, the Senate report and the Ro ma now report have made everal
suggesti o ns to improve the health care syste m and target issues such as ; increas in g funding , decreasing wait times,
providin g lirruted pharmacare, and a publi c v . a pri vate sy te rn. T he e are obviou ly very critica l issues and are
bein g addressed extensively. M y essay, however, is ju t going to focus o n an aspec t of o ur health system that I
be li eve can have a great impact o n the health of Canadi ans and the sustai nability of o ur health care system.

The push towards prevention
I propose the idea of a more pati ent centered approach to Medjci ne where pati e nts wi ll be e mpowered by
more knowledge about the ir own health . Alth o ugh thi i by no means a new concept, it is o ne that is ofte n side
lined as we face other challe nges in hea lth care today . However, by ed ucating patient about various illnesse a nd
promoting an e nviro nment of health y li ving we may be abl e to prevent many di eases and create better o utcomes.
Thjs will have an even greater impact in the nex t few years as our popul ati o n becomes demographicall y older. The
focu s on di sease preventi o n ca n go a lo ng way in ma king our Hea lth care system better and stronger.
Reali zing the fact that we have been reacting to pati ent illne s and di seases, rather than promoting
preventi on o f di sea e, th ere has been a recent push to be more proactive in primary prevention and promo ti o n of
health y living. T he most important way th at thi s can be acco mpli shed is through patie nt educati o n. Thi s is an
e normous challe nge in the ever-changin g culture of med icine and becomes even more signifi cant in a multi c ultural
nati o n like ours. Canad ians come from a diverse background of experiences and beli efs abo ut healthy li vinoo •
therefore, any approach to health pro moti o n must keep thi in mjnd .
Many initi atives have been taken to increase pati ent aware ness regardin g co mmo n illne ses. The CTFPHC
(Canadian Task Force on Preventive Health Care) and the IYH (It' s You r Health ) are two such initiatives. It' Your
Health (IYH), for exampl e, is a j oint publicati o n prod uced by Health Canada (HC) and the Publi c Health Agency of
Canada (PHAC) that provides informati o n o n a wide range of health and safety i sues. Other avenue of health
promotion have been hundreds of pam phl ets availabl e o n vario us topics, waiting room po ter and even television
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commercial for the most pre sing hea lth iss ues. Eve n th ough these are nobl e initi ati ves, the que ti on we must ask i
whe the r the e are e nough to accompli h the fi nal goa l.

The need for a better approach
We are mov ing toward a c ulture o f "e lec troni c medi cin e" whe re peop le arc abl e to ga in a lot of
informa ti o n thro ugh onlin e reso urces. Excell e nt webs ites have been crea ted to prov ide patie nts wi th more
informati on regarding common health issues. However, for eve ry good re ource, there are . everal othe rs whi c h
provide mi sinforma ti on. We can also not as ume that most peopl e will be ex po ed to the inform ati on o nlin e and
even if they are, whethe r it will provide the m with the correc t and prove n ad vice. Simil arl y, Hea lth Ca nada ha
created many pa mphl ets and doc ume nt to promote health y li ving a nd prov ide infonnati o n regardin g di sea. es.
However, impl y ha ndin g the m out does not mean that they will be read or even under tood by the majority of
people. I beli eve tha t thi s is where our first line of de fe n e, the primary care ph y ic ia n, has an ex tre mely im porta nt
ro le to play.
Pati e nt are quite recepti ve to the inform ati on prov ided to th em by their Famil y Phys icians and they respect
the m a medi ca l ex perts. Primary care ph y ic ian also have the uni q ue opportunity of deve loping stro ng a nd trusting
relati onship with their patie nts over a pe ri od o f years. Thi , coupl ed with the fac t th at mo t peopl e go to the ir
Family Physicia ns for routine hea lth c hec k-ups, make the m the fir t and mo t important line of de fe n. e fo r
preventi on and early de tec ti o n o f illnesses. There is no doubt that part of the ro le of a Famil y Phy icia n i to be a
health ad vocate a nd an educator f r the pa tie nts. However, thi s become very diffic ult kn owing the c urre nt shortages
of Famil y Physician and the overwhelming work load bein g faced by many of the m. The shortage of Fa mil y
Physicians is not lirnited to rural area or mall c iti e ; it i a probl em that spa n aero many o f the maj or c iti es of
the Country a well. It i certainl y unfortunate, but it seems that the foc us has turned away from qua lity toward
quantity.
Yet thi is not the fault o f the primary care ph y i ians, who mu t be comme nded for ab orbing a bi g part of
this health cri si and taking on the re ponsibility of minimi zing it effects o n patie nts. However, th is hi gh de ma nd
makes it diffi c ult to educate pati e nts about their health a nd illn esses. A recent urvey by the Co ll ege of Famil y
Physicians fo und that whe n on-call hours were included , famil y doctors typica ll y work betwee n 70 a nd 80 hours per
week. It is not diffic ult to imagin e that thi s pres ure o f time and the qua ntity of pati e nts has a n effect on the am ount
of time that can be pe nt talking to pati e nt about common health care topic . A comprehe nsive li st of uch topi cs
would be too long, but they include common things uch as: Exercise, di et and nutriti on, healthy li vin g, Pregna ncy,
creening exam and their importa nce, e ffect o f moking, di abe tes, hyperte nsio n, ri sks of STD , u e contracepti ve ,
well -baby care, effects of alcohol abuse and many more. Again, I have ju t li sted a fe w topi c to give an idea of the
type of things patients can be give n more educati on about.

A possible solution .... PCAPP
Keeping in mind the limited time and resource in the hands of the fa mil y ph ysicians a nd the e normous
ta k of patient education, I make the suggesti on of a group ba ed approach to pati e nt educati on whi c h I call the
People centered approach to primary pre ve nti on (PCAPP) . The proposal is for small gro up se io ns co nduc ted by a
famil y ph ysician for tho e people in their practi ce who may be interested in the topic . Thi approac h all ows the
physician to provide more detailed informati o n about a partic ul ar topi c and al o a nswer the que ti ons o f the pati e nts
in that group . The group can meet for a ses. ion o f about Y2- l hour and the ph y icia n would be all o wed to bill for the
services he or she prov ides. This i also economi call y fea ibl e a a greate r number of patie nt will be targeted in a
small amount o f time. Let me elaborate on thi s a little more using the exa mpl e of hyperte n ion.
Let u ass ume th at Dr. John i a fa mil y physicia n with a busy prac ti ce of 1500 pa tie nts. There is no doubt
that several of hi s patie nts will have hyperte nsion (whic h i the most common reason for visits to a fa mil y phy ic ian
and a di sease effec tin g up to 22% of Canadi ans) . Dr. John may set up a ·· Living with hypertension " talk for a group
of interested patie nts for an hour on a weekd ay evening. The talk will target not onl y tho e patie nts who have
hyperte n ion, but it can also be geared towards those wh o have borde rline hi gh bl ood pres ure. The pati e nts will be
more recepti ve to a session where they will be getting importa nt info rmati on from omeo ne who m they trust a nd
who has been providing them with care.
Dr. John may .di scu s impo~tant i ue as ociated with hyperte nsion, including preventi o n, ma nageme nt,
ide e ffe~ts of med1 cat10n , an? the Importa nce of exerci e a.nd diet. The goal will be to provide simpli sti c, yet
valuable mformat10n to the pa~1 e nt so that they become more mformed about their co nditi o n and can Jearn to better
manage it them el ves. The pat1ents can also ask any questi ons they may have about hyperte n ion. It also prov ides an
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avenue for furthe r di scu io n tha t the pati e nt can have with Dr. John in a more confide nti al and o ne to o ne e tting.
Thi s, in bri e f, is the type o f approach th at I be li e ve can go a long way in impacting patie nt health. Dr. John Will be
re mune rated for this talk a nd it will be billed to the provinc ial nl.ini stry o f hea lth . Thi s will be cost effecti ve becau e
in V2- l hr the ph ysic ia n will be a bl e to target 6-8 pa tie nts and greatl y influe nce their kno wl edge a bo ut a hea lth topi C.
Thi wa obviously a simpli ti c ex pl a nati o n o f the pl an itse lf a nd it desired res ults. Some people may
wonde r why suc h a group based approach may he lp whe n we already have pa mphl e ts, informa ti o n docume nts a nd
othe r re ource avail able for pati e nts. As I have me nti o ned prev ious ly, the e docume nts most certainl y exist, but can
be of no ub titute for the informati on prov ided by Fa nl.il y Physic ia n . The docume nts may not be unde rstood , if
read a t all , because pati e nts ofte n ta ke the word of their doc tors in whatever they are being prescribed or to ld to do.
The goa l of thi proposal to promote a more pati e nt centered approach to preventi on and earl y de tecti on of disease.
It may all ee m g od o far , but I am in no positi o n to c laim tha t there are no c hall enge with thi s approach.

The challenges with PCAPP and how they can be overcome
The firs t c halle nge I ee in the impl e me nta ti on of uc h a pl a n is the w illingne s of Fanl.il y Physicia ns to ho p
o n board with uc h a proposal. After all , they will be front a nd centre in this mall groups a pproach to pa ti e nt
cente red preventati ve care. As I have me nti o ned above, phys ic ia n a lready fee l they are be ing overworked due to
inc rea ed pa ti e nt load . T he questi o n the n becomes how they will buy into uc h a n a pproach. I think the soluti o n to
thi s i two-pro nged . First, phys ic ia ns must be a n acti ve pa rt in the deve lopme nt of uch a program a nd seco ndl y,
they sho uld fee l th at their e ffo rts a nd time will be re mune rated well. The be tte r the physicia ns fee l a bo ut the
program a nd its outcomes for the m a nd the ir patie nts, the greate r the po ibility of success. The nex t importa nt iss ue
the n beco me that o f funding .
T he funding for thi s proposal sho uld come fro m the nl.ini try o f hea lth to whi c h the Fanl.il y physicia n ' bill
fo r the ir service . Thi s will be no differe nt tha n a pati e nt con ult, except that it will be muc h more th oroug h, mo re
producti ve a nd econonl.i call y feasible a a greater number o f pa ti e nt will be targeted in a mall peri od of time. The
Prov in cial nl.ini stri es of health can get the fundin g for the program from the fede ral governme nt. Again , fund s tha t
a re be ing u ed in other areas o f primary pre ve nti o n can be used t o ff e t o me of the co t of starting up suc h a
progra m. Agai n, be nefits of thi s project will certainl y o utweigh the costs to the yste m. A greate r c halle nge tha n thi s
may be tha t o f c reating a sta ndardi zed progra m.
Although the re will be fl exi bility in how the ph y ician conduct the e group se io ns, it will be he lpful to
have o me tandardi zed features. The de igning o f a sta ndard modul e would require input fro m fanl.il y ph y icia n
fro m a varie ty of practice . T he c hall e nge in thi s could be co-ordina ti on a nd coll a bora ti o n of the ma ny pe rsonne l
who may be in volved with suc h a large ini tia ti ve. However. I fee l tha t thi i ue can be ea il y re olved by
de ig na ting a body of respected physician who can come up with a imple sta ndardi zed a pproac h to these group
essio n , o utlining the ir goa ls and obj ec ti ves. It will a lso be he lpful if the nl.ini stry of hea lth provide all physic ia ns
with the ma in obj ecti ves for a parti c ul ar to pi c a nd a ny ha ndout th at the pati e nt ho uld receive. T hi s task will no t be
very di ffi c ult as the re is a lot o f informati o n a nd re o urces a lready cr ated by Hea lth Canad a. Reading the pro po a!
so far , o ne must ce rtainl y wonde r a bout the poss ibl e in vestme nt o f time tha t thi s project will take.
A major c riti c ism o f the project may be th at o f the amount of re o urce needed , primaril y time a nd space.
However, as I have o utlined before, reaching out to a large numbe r o f pa ti e nt in a hort pe ri od o f time i the
stre ngth of th is project. There is no do ubt that the ph y ic ia n may have o me di ffi c ulty cheduling a time conveni e nt
for the m. e lve a nd the pati e nts, but I think thi s is a minor hurdl e . Sinl.il a r to thi s i sue is that o f pace avail a bility,
because 6-8 peopl e will require m re pace th an a sta ndard exanl.ining roo m a nd since most clini cs do n' t have a
large co mmo n roo m avail able, the be t opti o n ee m to be a n e mpty waitin g room. The iss ue of timing and pace
ca n be easil y re o lved if the fa nl.il y ph ysicia n boo k a half ho ur to a n ho ur afte r a day' c lini c (i.e. the c lini c ho urs
ca n be reduced by one hour to accommoda te the pa ti e nts). The tinl.ing will uit mo t pa ti e nt and the wa iting roo m
will be ava il abl e to co nduc t these sessions. Rea li zin g tha t these ses ions will be weekl y or bi -weekl y a nd both the
pati e nts a nd the ph ys icia n will get re warded for the ir time (the pati e nt with valua ble informati o n a nd the
physicia ns with re munera ti o n), thi s does not see m to prese nt a sig nifi cant c halle nge in goin g a head with thi s
progra m.
So far in thi s essay , I have not di c ussed in a ny de ta il the pati e nt' pe rspecti ve in my proposa l. The two
most importa nt c ha lle nge. I ee from the pa tie nt's perspecti ve are interest a nd confide nti a lity. It nl.i ght initi all y be a
c ha ll e nge to get e nough pa ti e nt inte rest in the new progra m. Thi s issue ca n be tackled by waiting room po te rs a nd
recomme nda tion made by the fa rn.il y physicia ns or other taff me mbe r . The pa rti cipa ti o n will be comple te ly
vo lunta ry a nd I think th at pa ti e nt. will be pl ea ed to get more informati o n abo ut conuno n hea lth topi cs a nd
ma nageme nt of di sea es. I think pati e nt interest will vary fro m topi c to to pi c , but in gene ra l pa tie nts will be
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recepti ve to a g ro up ba ed approach to learnin g abo ut commo n hea lth i ues. PCA PP will a l o a ll ow patie nt to gain
greater kn owledge a they may ge t an wers to que ti o n they may fee l intimidated to a k them e lve . T he eco nd
is ue, a nd in my o pinio n the bi ggest cha lle nge to thi s progra m, will be tha t of o nfi de nti a lity.
Co nfi de nti a lity is a n importa nt as pec t o f pro pe r medi ca l care and at no po int ho ul d a ny pa ti e nt 's co nfi de nti a lity a nd
afe ty be j eopardi zed . Thi can be a poss ibl e c ha ll e nge fo r top ic uc h as cancer o r ex ua ll y tra nsmj ued d isea e ,
whe re the pati e nt may no t want others to make a sumpti o n abo ut the m o r they may fee l inti mjdated t alle nd .
However, by de ig ning the group se io ns ar o und impl e and le s c ultural or oc ia ll y sen iti ve top ics, thi c ha lle nge
can be ea il y overcome. D i c u io n uc h as hea lthy li ving, proper exe rci in g, nutriti o n. hyperte nsio n, preg na ncy,
we ll-baby care e tc . do not po e a ignifica nt c halle nge in thi area. If pati ent are properl y info m1ed abo ut the
tructure and purpo e of the se s ion , it wi ll further reduce a ny i ue regard ing breac h o f co nfid e nti ali ty . Fi na ll y,
the p rogram i 100% vo luntary and n pati nt will be a ked to parti c ipate with utth ir approva l.

Conclusion
It i

aid that a ll th at glitters may no t be go ld , but unl es we look carefull y how can we rea ll y know?
There fo re, to asses the prac ti ca lity and be ne fit s fro m the pro posed program ca n be assessed mo re tho ro ug hl y if a
pil ot tudy i do ne. T hi s i the hope in whi c h the a uth or ha writte n thi pro po at. The pil o t study ho ul d in vo lve
evera l willing farrul y phy ic ia n , fro m a varying range o f prac tice type , who will run these 3-4 gro up sessio n to
a ess the overa ll effec ti venes o f thi gro up ba ed approach to preventati ve care. T he a pee l. that would need to be
a e ed are: u e of time and re o urce , pati e nt intere t, phy ic ian' rev iew of the es io n and the associated co ts .
Most o f the e ca n be tudied quite ea il y and the pati e nt's viewpo int can be tudi ed thro ug h a que ti onna ire. A pi lot
tudy will reall y he lp to gage the tre ngths a nd wea kne ses of thi pro posal a nd if it has any po sibl e ro le in the
future of o ur health care y te m.
The CAPCH ha do ne a great j o b of timul ating tho ught a nd bringing o ut idea th at may po te nti all y he lp
our great health care syste m. I am a firm be liever in the fund am e ntal values that ma ke up the Canadia n Hea lth care
y te m, but in o ur pa io n we ca nno t fo rget that there i till much room for improve me nt a nd we, as a peopl e, mu t
fi nd avenue to overcome the chall e nges facing the yste m. The People cente red approac h to primary preventi o n
(PCAPP) i a humble uggesti o n whi ch may be a building to wards a stro nger and mo re viabl e health care sy te m.
By providing patient with info m1ati o n abo ut comm o n hea lth care topi cs we ca n e mpower the m to make better
choice and pro mo te healthy li ving. Critical analy is and furth er in ve li gati o ns abo ut PC APP may yie ld greater
in ight into ways that people can be mo re informed abo ut the ir hea lth . I e nd with the wise words of T o mmy
Dougla "M y frie nds, watch o ut fo r the little fe ll ow with an idea".
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Feature Article
Pharmacologic Considerations in an Elderly Population
Wendy Ng, Meds 2009
Usuall y, elderl y pati ents have more ongoing health concern th an younger
patie nt . T o date, there have bee n few reviews that examine the be ne fit and chall enges
to pre ribing co mmo n medi c ine for a geri atri c p pul ati on. Overall , NSAID ,
anticho linergics, neuroleptics and be nzodi azepine have seri ous side effects th at are
more ofte n manife ted in the e lderl y. Based upon the increased danger of
pharmacolog ic ad ver e events in the o lder popul ati o n, careful co n iderati on of the
be ne fits and ri ks of the e medi cati ons i e enti al. It re main s useful for c lini cian to
co nsider afer altern ati ves when writing prescripti o ns.

This article has been reviewed by Dr. John Greenaway.
In general, elderl y pati ents have both chro nic and multipl e di seases. Consequentl y, po lypharmacy is a maj or
factor in the preva lence of adverse drug reacti on , which increa e in inc idence with pati ent age. In additi o n, e lderl y
patie nts have poorer ho meostati c re ponses to physio logic chall enges. A variabl e rate of declining organ and ti s ue
functi on amo ng di fferent e lderly indi viduals further complicates attempts at predi cting patie nt re po nse to
pham1aco logic therapy. Finall y, with poorer compli ance to drug regiments, due to the complex iti e of timing do e
of many drug with different do ing chedules, sorting out pham1acology for elderl y pati ents can be a cha ll enge.
In both male and fe male , the proporti o n of total body weight as fat increa e with age. Fat i loca li zed to
the middle and upper b dy region a we age. In wome n, there i an additi o nal po tmenopau a l accelerati o n of the
fat di stributi on trend . B ody fat tend to accumul ate within organ . After a plateau in rising fat proporti o ns at
approx imately the sixth decade of life, a reducti o n in the amo unt of body fat foll o ws in eve n older ages . 1
B ody water as a percentage of total body weight dec lines with increa ing age. Furthem1ore, organ fun cti o n
tends to decrease with increasing age. Kidney glomerul ar filtrati on decrea e , a measured by creatinine clearance.
At the ame time, serum creatinine co ncentrati o n may not appear e levated, despite re nal impa irme nt, due to the
decrease in serum creatinine co ncentrati on from lower levels of musc le ma as we age. In additi o n, li ver ize a a
proporti on of body weight decrea e , leading to decreased total hepatic blood fl o w and poorer e limi natio n of many
drug fro m the body, parti cul arl y lipophili c drugs th at ha ve a hi gh hepatic ex tracti o n rati o. Cardi ac output decreases,
whi ch may be due to a co mbin ati o n of sedentary life tyle, progre ive ti ssue degenerati o n with age, or di ease.
Blood perfusio n o f ites of body drug e limin ati on can be inadequate in cardi ac failure. With a decrea ed
baroreceptor refl ex, a. well , o lder pati e nts are at greater ri k o f orthostati c hypotension. 1
Ba ed o n the e compl ex interactio n and a multitude of fac tors, pharmacology for e lderl y patie nts requires
extra cons iderati on. The bene fits and ide effect of NS AJD (non- tero ida l a nti-infl ammatory drugs),
anti cho linergic drug , ne uro le pti c and be nzodi azepine merit di cu sio n, a the ir uses have important impli cati o ns
in thi s popul ati o n of lder pati ent .
NSAIDs (Non-steroidal anti-inflammatory drugs)
NSA IDs (non- teroida l anti -infl ammatory drugs) act by inhibiting the cyc looxygenase required for
conversi n of arachid o ni c acid to e ndoperox ide intermedi ates (PGG 2 and PGH2). Thi lead s to antipyretic,
ana lgesic and pl ate let-inhibitory e ffec ts. There are also e ffects on rheumatic, infl ammatory and immuno logical
processes, as well as on acute go ut. This cycl oxygenase inhibiti on is either readil y or lo wl y rever ible , unlike that
2
of acetylsa li cy li c ac id.
Side e ffects o f NSAJD use include agra nul ocytosi , which i no t een with ali cylate use. A with a li cy late
use, NSAID ca use gastri c muco al damage because they are weak organi c acid s, a nd inhibit prostaglandin ynthe is
and accumul ate intrace llul arl y due to the ac idity of the gastri c lumen. Thi is re lated to no nse lec tive inhibiti o n of
both COX- 1 and COX-2 isoenzymes in vo lved in prostaglandin synthe is, where COX-1 ge nerate pro tano id
required fo r the mainte nance of ga trointestina l mucosa and pl ate let aggregati o n, whereas COX-2 i required fo r
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ge ne rating prostag landins that modify inn amma ti on and pain . Ga tri c bleed , anemia, ep iga tric pain , he mate mesis,
dy pe psia, ulcerati ve e oph agiti a nd ul cerati on and perforati on of the gas trointestin al syste m have all bee n reported
with NSAID use. Pepti c ul cer di ea e is more igni fi ca nt in the e lderl y due to the hi ghe r preva le nce f Helicobacter
pylori a nd th eir more co mmon u e o f NSAIDs, compared to the ir yo unger counterparts' use o f NSAIDs.
In additi on, the ynthes is o f thromboxanc A2 whi c h is de ri ved fro m cyc li c e nd operox ides PGG2 a nd PGH2
fro m arac hidoni c ac id by cyc looxyge na e i reversibl y inhibited , suc h th at pl ate lets may fa il to aggregate.
Pro tacycl in (PGI2), whi ch oppo e pl a tele t aggregati on, may be inhibited by NSAID due to the co ncentrati on of
2
cyc looxygenase acc umul atin g in e nd otheli al cell s. Interac ti ons with warfarin ca n cause serious bleed ing.
In renal fun cti on, pro tag la ndin s are importa nt for increasin g g lome rul ar filtration rate, dec reasin g re nal
va c ular resi lance, increasing natriuresi a nd reducin g water rea b orpti on in the loop o f He nle. Prostag landin s may
also prevent antidi rue tic hormo ne acti on on tubul ar e pithe lium through nega ti ve feedback, to increase water
eliminati on. Howeve r, N AID inhibit pros tag landin synth esis, thus all wing exces ive wate r rete nti o n and ede ma
formati o n. The side effec t of edema, fluid and electro lyte di turbances, odium and c hl oride re te nti on, a nd pl as ma
diluti on can be da ngerou .2
O ther side effec ts o f NSAIDs related to cyc looxyge nase inhibition include ac ute rhiniti s, urt icari a,
bronc hocon tri cti on and hypote n ion in pati e nt · utTering from asthma, chroni c obstruc ti ve pulmonary di sea e o r
other lung ailme nt . Finall y, ad ver e effec ts that are like ly unre lated to cyclooxygenase inhibiti on ca n affect all body
2
sy te rns, ra nging from headac he, di zzines and rash to mya lgia, tinnitus and tl atul e nce.
The long-term prescripti on o f NSAIDs (non- teroida l anti -infl a mma tory drug ) to treat osteoarthr iti s fo r
3
pati ents with a hi tory o f pe ptic ul cer may cause recurre nce o f peptic ulcer, due to gastri c irritation. No n-drug
therapy, or acetamin ophen, or NSAID with gastroprotec ti ve agent is reco nm1e nd ed instead . In pati e nt with c hroni c
re nal failure, NS AIDs may worsen re nal failure, ca using alt and wate r re te nti on. Aga in, no n-drug the rapy, fo ll owed
by acetaminophe n as necessary, i recor1m1e nded as an alternati ve. In pati e nt already receiving warfarin , NS AIDs
may cause increa ed bleeding. In pati e nts with a hi tory of hyperte nsion, NSAIDs may cause salt and water
4
rete ntion and exacerbati on o f hyperte nsion. Thus, acetarrunophe n is prefe rabl e .

Anticholinergic Drugs
Anticholinergics (muscarini c bl ockers) can be used to correct the dopamine/acetylcholine imbalance in
Parkinson' di sea e, by lowering the acetylcho line acti vity level. Atropine- like drugs such as be nztropine and
trihexyphenidyl can be used . Howe ver, unpl ea a nt side effect of blurred vision, dry mouth , co nstipati on, urinary
re tenti on and ataxia may occur. Thi s is becau e sali vary ecre ti on i impaired , so swall owing al o may beco me
diffic ult. Ga tric secretion is dimini shed, bro nc hi al ecreti on are suppressed , and sweating is impai red . A uc h,
anti cholinergics have not been used as first line agents for Parkin on's di sease since the introducti on of L-dopa. 5
Al zheimer' di sea e i the fourth largest cause of death in peopl e over the age of 65 , a nd is the most
6
co mmon form of de me nti a. Ch olineste rase inhibitors are conm1o nl y used in the treatme nt o f A lzheime r's di sease
related deme nti a. Donepezil , galanta mine or ri vasti gmine are o fte n prescribed .7 While c ho linesterase inhibitors have
not been conclusively shown to reverse or slow down mild cogniti ve impairment, the re are numerou rando nu zed
clinical tri als th at show th at cho line tera e inhibitors slow the progre sio n o f Alzheimer's de me nti a. Thi s ha been
suggested to be due to the role o f mu carini c receptors in ne urotrophic regenerati o n, and acetylc holine te ra e
inhibitors' role in restorati on o f ni cotine receptor acti vity. It ha also bee n shown th at cho line tera e inhibitor can
inhibit be ta-amylo id pl aque formati on by impactin g secre ti on o f the amyloid precursor prote in (APP ). 8 The e drug
do not stop the proce s of ne urodegenerati o n. Ne we r trategies o f combating Alzheimer' disea e inc ludes
me mantine, a NMDA-receptor antago ni st that ha been re ported to be effec ti ve th erape uti ca ll y in A lzheimer's
6
di ea e, and may be a better alternati ve.
In contra t, due to its po sibl e oppos iti on of be ne fi cial e ffect of cholin este ra e inhibitors, anti c ho line roic
medicati ons are notorious for wor e ning cogniti ve fun cti on in su ceptible pati e nt . Pati e nts with de me nti a a nd u~ge
incontine nce who nught benefit from both an anti cholinergic medicati o n a nd a c holine tera e inhi bitor pre e nt a
challe nge to the cli~i c i a ~ , as it eems that the two drug theore ti call y work again t o ne another. Whil e the drug
combin ati on is poss1bl ~, rt can be an 1mperfect means of treatme nt, but no ra ndonu zed contro l tria ls for suc h case
have yet been reported .
The prescription o ~ anti cholinergic drug to treat irritabl e bowe l syndro me for pati ents with de me nti a may
wor e n cognitive and beha viOural fun c tr on. In stead , nondrug a nd di et therapy, and a ca lcium cha nnel bl ocker to treat
diarrhea, are recomme nded . The prescripti on of anti cho linergic drugs to prevent extrapyramidal e ffec ts of
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antip ycho ti c drug may cause agitati on, delirum. and impaired cognition. Instead, decreased dosages of
4
antipsycho ti c drugs or the rea sess ment of need for these drugs i recommended .

Neuroleptic Drugs (Antipsychotic Drugs)
Neuroleptics are types of antipsyc hotic medi cati ons. Anti psychoti cs can be u ed to treat psychosis that may
be e ncountered in pati ents with evere deme nti a, depress ion or severe metabo li c di turbances from liver failure or
kidney fa ilure. Whe n given to pati ents, the e drugs prod uce decrease in bi zarre behaviour, delusio ns, and
hallucinati ons. They al o decrea e anxiety, and pro mo te leepine s or edati o n. In the early 1950's, Laborit, a
urgeon in Pari s. no ted th at vario us antihi stamine drugs s uch as promethazine had a ca lmjng effect o n postoperati ve
patients. In 1950, Charpenti er synthesized chl orpro mazine, a related compound , which reduced both the need for
10
surgica l anae the ti c and patients' anxiety. A uch, p ychi atrists began to u e the drug for treating psychosis.
Mo t antip ychoti c act e lecti vely o n dopamine receptors, bl ocking doparrune receptors due to their
irnilar tructure to the dopamine mo lecul e, such a chl orpro mazine (a phe nothj azine) a nd haloperidol (a
butyrophenone). Antip ycho ti c ac ti o n seems to be more c lo e ly linked to D2 than to Dl a natagoni sm.
Antip ychoti c can a l o block the actj ons of L-dopa, apomorphine, and bromocriptine, whjch are all d opamine
agonj t . In additi o n, the che moreceptor tri gger zone outside of the blood-brajn barrier in the reti cular formation of
the med ull a ob lo ngata, whj ch stimul ates nausea and vorruting, i ri ch in 0 2 receptor . Thus, antipsycho ti cs a lso have
an effect of reducing nausea. As such, antipsychotics can reduce nau ea produced by o ther drugs , pregnancy,
radiation sickness, and cancer. 10
Most side e ffects of antipsychotics ari se fro m their cholinergic, adre nergic and hi starru nergic recepto r
acti ons, becau e their antipsychotic effects ori gin ate from their antidopaminergic ac ti ons. Peripheral side effect
include hypotensio n, constipati on and tachycardia. 10 Other side effects inc lude antipsychotic-induced parkinsonism
from effec t on the nigrosti atal pathways, dyskinesia and dystoni as, and akathi ia, and later tardi ve dyskinesia over
month or year . In a study of 56 older psychi atri c patj ents, even after contro llin g for pontaneous extrapyramida l
sig n at ba e line and for natural flu ctuati ons, there was a substanti al risk of neuro leptic-induced parki nsoni sm in
11
patients treated with very low doses of neuro leptics. In ano ther group of over 3500 pati e nts aged 65 to 99 e nrolled
in a Med icaid program in Massachusettes, pati ents were found to be 5.4 time more likely to require
antiparkinsoni an medication if they were taking neurole pti cs, a compared to non-users. Ne uro leptic use is well12
known and comm on cau e of ex trapyramidal dys func ti o n in the e lderl y.
Neuroleptic mali gnant syndrome is a rare but severe ide effect, wru ch include extreme rigidity, fever ,
marked autonomi c di sturbances and muscle destructio n. Unwanted edati o n can be due to a compl ex interacti on of
anti_hi tarru nergic , anti adrenergic and anticho linergic actions. Orthostatic hypote n ion occur because antip ychoti cs
depre blood pres ure by dilating the arteri o les thro ugh directl y actin g on alpha-adre noceptors respo n ibl e for
vasoco nstriction . There may also be a direct effect o n the vasomotor ce ntre, contributing further to hypote nsion.
Anti cho linergic effects can lead to mydri a is and weakened c iliary musc le , cau ing mydri asis. Decreased tear
secretion can lead to dry eyes, and mydri asis may decrease aqueou humor outfl ow and precipitate g laucoma in
certaj n pati ent . Dry mo uth , con tipati o n, and urinar y he itancy may a l o result from anti c holinergic e ffects.
Pseudopreg nancy, due to dopamine' s action on the pituitary to inhibit mammotroph ce ll pro lactin re lease, and
blockage of follicle stimul atin g hormone and luteini z ing hormo ne may lead to anovul ati o n, lack of menstruati o n and
hyperpro lactinemja, swo lle n breasts and galactOIThea . ln pati e nt pred i posed to seizure , antipsychotic can
produce eizures, mo t promjnently with low-pote ncy agent . M ore rare ly, phe nothi azine- induced j aundi ce and
dermatiti s and ph o tosensiti vity may occur with antipsycho tics. 10
The pre cripti o n of chl orpromazine to treat p ycho i for pati ent with a hi story of postural hypote nsio n
may wor e n po tural hypote nsion and ca u e falls . Alternatively, hi gh-potency neuro leptic such as haloperido l with
bl ood pre sure monitoring is reco mmended. 4

Benzodiazepines
C hl ordi azepox ide was the first be nzodiazepine marketed in 1960, foll owed by di azepam in 1963 and
oxazepam in 1965. All benzodi azepines are variation upo n the 5-aryi- J ,4-be nzodi azepine nucleus. Diazepam a nd
ma ny other benz di azep ines are metabo li zed to the active metabolite N-de methyldiazepam, also known a
nordi azepam. In 1977, specific receptors for be nzodi azepines were di covered in the nervo us ystem . Type I
receptors are abundant in the cerebe llum, cerebral corti cal layer IV , and the sub tanti a nigra. In co ntrast, Type II
receptor are located in the hippocampus, superi or co lli c ulu and cere bra l corti ca l layers I-III. It is be li eved tha t bo th
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anxio lyti c and sedative effec ts are medi ated through the Type I rece ptor , wheras anticonvul sa nt and muscle
relaxati on effects are med iated through the Type II receptors. The be nzod iazepin e receptor may also be lin ked
coope ratively with GABA receptor , since GABA a nd GABA agoni sts have been shown to e nha nce be nzodiazepi ne
receptor binding a bilitie . 13
Benzodi azepines have an anti a nxie ty ac ti on. M o t be nzod iazepine have been approved for use in ac ute
a nxiety di order . Since effi cacy decrea es a bit after a few weeks, the drugs are less use ful in the treatme nt of
c hroni c anxiety. Be nzod iazep ines also have anti co nvul sa nt ac ti vity, but to le rance to th e an ti convul sant effec t can
deve lop with lo ng-term use. M os t benzodiazepine are useful in alcoho l withdrawa l syndrome treatment.
Be nzodi azepines are also use ful for thei r musc le re laxant effects, uch as in treating ne urom uscul ar di sorder li ke
cerebral palsy a nd te ta nus. Furthe rmore, be nzod iazepines are useful for ac hi ev ing amnes ia with sedati on. Fi nall y,
be nzodi azepine can treat the ymptom of in omni a. Since elderl y patie nt are more se nsiti ve to the effects of suc h
drug , initi al dose in pati e nts over age 60 hould be 50% of the li sted dose requirements for insomnia. The most
common ide effect i a feeling of sedati on or mental " fuzziness" in the morning. Pati e nt must at o be re minded
13
that no hypnoti c drugs sho uld be taken with alcohol , which can be a fatal co mbinati on.
Co mmon side effec ts of drow ines , atax ia, le th argy a nd rarely coma occ ur in les th an 10% of ho pitalized
patient that receive oral be nzodi azepine . 13 Delirium, oversedati o n, and hypote n ion are other major side effects.
Lorazepam ha been found to be assoc iated with the more seri ous side effects of ataxia and delirium, which could
re ult in pote nti all y debilitating acc ide nts, inc luding fall a nd fractures. 14 O the r side effect inc lude : inte rfe re nce
with memory a nd reca ll , a nd ante rograde a mnesia. With intravenous admini stration of be nzodiazepines, important
13
but uncommon side effects inc lude: respiratory or cardi ac arre t, hypote nsio n, and phl e biti s at the inj ect ion site .
The long-term prescripti o n of long half-life benzodiazepines to treat insomnia or anxiety may cau e fa lls,
fracture , co nfusion, de pe nde nce and withdrawal. Alternative inc lude non-drug therapy or the usage of hort halflife benzodiazepine . Similarly, the long- term prescripti on of a long half-life be nzodi azepine to treat agi tatio n in
4
dementia may be repl aced by loxapine or haloperidol, or a hort half-life be nzodi azepine.

Summary
Overall , NSAIDs, a nti cholinergics, ne uroleptics and ben zodiazepines have both important and erio u side
effect that are more pronounced in the elderl y. B ased on the susceptibility of older patie nts to ad verse events from
pharmacologic effect , careful considerati on of the advantage and di ad vantage of these medi cati ons re mains
valuable. Before prescribing these medications, it is useful for clini cian to fir t consider safer alternatives for their
elderly patie nt .
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One Vision ... Four Sites
With the opening of the new Emergency department (January 2007) and the
opening of the Durham Regional Cancer Centre (May 2007), this is an exciting
time to join Lakeridge Health, one of the larger hospital networks in Ontario,
located 45 minutes east of Toronto, in beautiful Durham Region. Through our
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settings, we offer a broad range of healthcare services.
In today's dynamic work environment, our dedicated healthcare professionals
and supporting team use our Better Together approach to provide excellence in
patient care and service. This is enhanced by our dedication to Health Services
Training and Research, through the Academic Liaison program and the newly
created Lakeridge Health Services Institute for Training Education and Research.
As well, nearby universities and colleges, including the newly created university
centre- the University of Ontario Institute of Technology, and Durham College,
offer excellent lifelong learning opportunities.
For more information on Physician opportunities please contact:
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www.lakeridgehealth.on.ca

BOWMANVILLE

OSHAWA

PORT PERRY

WHITBY

GUARANTEED BEST VALUE
• Ophthalmoscopes/Otoscopes
• Surgical/Procedure Masks
• Examination Table Paper
• Blood Pressure Products
• Electrocardiographs
. • Needles & Syringes
• Physician Supplies
• Surgical Supplies
• Stethoscopes
• Exam Gloves

~

Welc~Allyn·

3M
MIDMARI<

BD

